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Abstract: Wastewater epidemiology is a noninvasive tool that uses wastewater as a means 
to gather nondiscriminatory information about the exposure of a group of people to drugs, 
toxins, and diseases, which is accomplished by analyzing the wastewater for the analytes 
of interest.  This study aimed to develop an analytical method for the simultaneous 
detection of 57 prescription and illicit drugs and their metabolites in wastewater obtained 
during sporting events. The epidemiological data obtained from this study can be used to 
inform public health and safety entities about the current use of prescription and illicit 
drugs in the community.  Wastewater samples were obtained from a football stadium 
several days prior to and during a game day, extracted via solid-phase extraction, and 
analyzed with liquid chromatography-tandem mass spectrometry. The analytes of interest 
spanned several drug classes, including stimulants, opioids, benzodiazepines, and illicit 
drugs such as cocaine and PCP. Of the 33 samples analyzed, 28 of the 57 compounds of 
interest were present in at least 1 sample, with 100% of samples containing at least 1 
stimulant, opioid, and illicit drug, and 24% at least 1 benzodiazepine. The findings are 
generally consistent with self-reporting from the community where the samples came 
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Pharmaceutical and illicit substance abuse is an ongoing issue within the United States. 
The “opioid epidemic”, a colloquial term for the recent rise in opioid overdoses, is currently the 
focus of nationwide media attention, lawsuits against pharmaceutical companies, and proposed 
public policy changes. According to the Centers for Disease Control and Prevention’s National 
Center for Health Statistics, more than 45,000 Americans died in 2017 from opioid overdoses1. 
Current methods for obtaining statistics like these are largely based on indirect estimations 
obtained from national surveys, police arrest and hospital records, and drug testing program 
reports2,3. One of the major sources of drug abuse statistics comes from the Substance Abuse and 
Mental Health Administration (SAMHSA). SAMHSA issues an annual drug abuse report 
containing self-reported drug use data obtained from the National Survey on Drug Use and Health 
and the United States Census4.  
Unfortunately, each of the aforementioned methodologies for measuring drug use is 
accompanied by underlying flaws, potentially leading experts to underestimate the severity of the 
problem. National surveys such as those used by SAMHSA, often have large gaps between 
successive measurements and rely on self-reporting. Personal drug use is a socially stigmatized, 
private activity and as such, drug abusers cannot be relied upon to accurately report their drug 
usage. Additionally, knowing the identity or purity of illicit substances cannot be reasonable 
expected of drug abusers. Hospital and police arrest records are more reliable sources of data, but 
only account for the small fraction of the population they encounter. 
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Drug testing reports, such as those issued by Quest Diagnostics, only report on the portion of 
individuals from which tests were obtained, are subject to manipulation by individuals being 
tested, and present data obtained at different intervals5. 
Thus, the complexity associated with obtaining accurate public drug abuse data has lead 
researchers to explore innovative techniques. For decades, environmental scientists have been 
aware of pharmaceutical drug contamination in our watersheds, originating from sewage 
networks. These trace chemicals are deposited into waste water when drugs and their metabolites 
are excreted from their user’s bodies via urine and feces. Using well established methodologies 
within analytical chemistry to detect drug contamination in waste water lead researchers to 
develop a concept referred to as waste water-based epidemiology (WWBE).  
The purpose of this work was to develop a WWBE analytical method to detect drugs of 
abuse and their metabolites in waste water. Waste water samples were obtained near a football 
stadium during a home game and 3 days prior to the game. The hypothesis being tested is that 
drugs detected in waste water will be elevated when stadiums are in use for a special event with a 
larger population present. The data obtained from analyzing these samples was used to determine 
whether drug concentrations in waste water are elevated during football games when compared to 
times when the stadium is not in use. Additionally, this study serves a proof of concept for the 







REVIEW OF LITERATURE 
 
2.1 History 
While the presence of pharmaceutical drugs in waste water treatment plants (WWTP) and 
surface waters was established in the 1990s, the presence of illicit drugs and their metabolites was 
not seriously considered until 2001 when Christian G. Daughton first proposed monitoring waste 
water as a method for obtaining insight on the public’s use of controlled substances2,6–8. Daughton 
argued that monitoring WWTP offered an “unobtrusive, non-invasive” approach to surveying a 
communities controlled substance intake and eventually provide social scientists with real-time 
data2. Zuccato et al., the first researchers who attempted Daughton’s waste water analysis 
approach, analyzed composite waste water samples collected from multiple Italian WWTP for 
cocaine and its metabolite, benzoylecgonine9. The results of this initial study were promising, 
with estimates revealing a far larger incidence of cocaine use than traditional methods9. After 
receiving worldwide attention for the initial study, Zuccato et al. published a follow-up study in 
2006 looking for amphetamines, cannabinoids, and opioids in waste water collected from Italian 
and Swiss WWTP, with similar results10.  
These initial successes spawned thousands of additional studies across the globe. In April 
2007, the European Monitoring Center for Drugs and Drug Addiction (EMCDDA) held the first 
major conference among experts in drug epidemiology and WWBE to encourage collaboration11.
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Soon after in 2010, an international European research group, Sewage Analysis Core Group 
Europe (SCORE), was formed between institutions in Belgium, Switzerland, Spain, Italy, the 
Netherlands, Norway, and the United Kingdom12. Since its inception, SCORE has organized 
several large scale case studies in an attempt to develop standardized techniques, making it easier 
to compare relevant data and identify common issues3. An important aspect of SCORE is their 
publication of ethical guidelines related to using WWBE. The most recently published of these 
studies targeted 7 illicit drug residues and spanned 6 years, 4 continents, and 25 countries12.  
Following the formation of SCORE and subsequent groundbreaking studies, the 
EMCDDA held a second interdisciplinary conference in October 2015 to highlight the 
exponential growth and progress being made within WWBE3. Unlike the 2007 conference, which 
focused mainly on the development of the still novel WWBE approach, the 2015 conference’s 
mainly focused on the various issues plaguing WWBE3,11. Sampling and analysis technique, 
fluctuations in water flow, drug stability in waste water, back-calculation of drug use, and 
population size estimates were among the main uncertainties outlined in the 2015 conference3. As 
a result, many researchers are now focused on identifying and addressing these uncertainties. 
2.2 Waste Water Analysis During Special Events 
The most common application of WWBE has been to estimate local illicit drug use 
within the larger community3. Recently, the focus of many researchers has narrowed to smaller, 
controlled populations. Traditional epidemiological techniques have identified trends of increased 
substance abuse during weekends, seasonal changes, and special events. Understanding these 
temporary fluctuations in analyte concentration is a crucial factor in translating epidemiological 
data obtainable from large composite samples13. Additionally, using WWBE to further explore 
the impacts of these events can provide information that self-reporting cannot reliably predict, 
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such as the presence of emerging illicit psychoactive substances like mephedrone and 
benzylpiperazine14. 
One of the first major publications to explore these temporal variations, conducted over 
several years in Spain by Huerta-Fontela et al., revealed elevated concentrations of cocaine and 
amphetamine-type stimulants during weekends and the summer and winter seasons15. Later 
Metcalfe et al. conducted the first WWBE study in Canada, finding further evidence of a trend of 
increased cocaine consumption on weekends16. Lai et al. provided a more detailed profile of illicit 
substance variations in Austrian waste waters during Christmas and New Year’s, finding elevated 
cocaine and MDMA concentrations but baseline cannabis and methamphetamine excretion17. 
The first example of WWBE being applied at special events was in 2009 when Bijlsma et 
al. analyzed waste water effluent collected from an “important rock event”, finding elevated 
levels of Methylenedioxy-methamphetamine (MDMA) and the cocaine metabolite 
benzoylecgonine18. A similar trend of drug abuse at festivals was identified earlier in Australia by 
a cross-sectional survey correlating attendance of a music festival in Melbourne and higher illicit 
drug use than the general population19. Lai et al. later confirmed this trend in Australia by 
analyzing waste water obtained at an annual Australian music festival, finding a steady increase 
in cannabis, MDMA, methamphetamine, and cocaine use over several days in two separate 
years14. 
Sports tournaments such as the annual American football championship, the Super Bowl, 
have also been shown to influence illicit substance consumption13. In 2010 Gerrity et al. 
compared WWTP samples collected near a major United States city during Super Bowl weekend 
and a normal weekend13. They found that cocaine use increased during the Super Bowl while 
methamphetamine use slightly decreased13. Football stadiums provide the unique opportunity to 
observe the influence of tourism from the opposing team, previously identified weekend 
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increases, and the impact of special event attendance. Furthermore, there are less unknown 
variables involved since population can be determined by ticket sales and increases in flow rates 
are more predictable (e.g. half-time). Gul et al. were the first to analyze effluent from a football 
stadium located at the University of Mississippi in a groundbreaking four part study20. Each part 
of the study focused on developing a method to analyze the same wastewater samples for the 
different classes of commonly abused substances: stimulants, opiates, benzodiazepines, and 
miscellaneous drugs20–23. In each study, increases in drug concentrations were observed during 
games and variations occurred depending on which away team was playing20–23. 
2.3 Laboratory Techniques 
 The majority of WWBE studies use solid phase extraction (SPE) to isolate and 
concentrate compounds prior to analysis via liquid chromatography-tandem mass spectrometry 
(LC-MS/MS). Another common method of analysis is gas chromatography-mass spectrometry 
(GC-MS). However, GC-MS is quickly being replaced as the gold standard for toxicological 
analysis due to recent advances in LC-MS/MS technology.  
2.3.1 Solid Phase Extraction 
 Waste water by nature contains several contaminants that can interfere with the detection 
of any drugs and metabolites that might be present. Additionally, the volume of water present in 
sewage systems dilutes the analytes of interest significantly, making them difficult to detect. SPE 
is a multi-step process by which sample is passed through a column containing a sorbent bed of 
micro-particles, 20-40 microns in size24. These micro-particles are typically composed of 
hydrocarbon chains, phenyl rings, and positively and negatively charged sites bound to silica24. 
As the aqueous sample passes through the sorbent bed, polar organic compounds suspended in 
solution such as drugs and metabolites bind to micro-particles, allowing water and undesirable 
compounds to flow through as waste24. The sorbent can then be washed to remove any unwanted 
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materials caught in the sorbent and dried to remove excess water. The sorbent-bound analytes can 
then be eluted using an appropriate organic solvent24. Lastly, to further concentrate the elution, 
organic solvent can be evaporated off by applying pressure via an inert gas such as argon or 
nitrogen, and the eluent can be resuspended in a smaller volume of solvent that is appropriate to 
the method of analysis. 
2.3.2 Liquid Chromatography 
 The principles of liquid chromatography (LC) are similar to SPE in that a column 
containing micro-particles is used to separate chemical compounds. However, in the case of LC, 
micro-particles referred to as the stationary phase are packed throughout a temperature controlled 
column in which a pressurized liquid mobile phase flows through24,25. Modern LC columns use 
far smaller particle sizes than SPE, less than 10 microns, to achieved greater analyte separation25. 
The use of such small particles generates immense pressure to achieve desirable mobile phase 
flow rates, thus most modern LC is high pressure liquid chromatography (HPLC)25. 
Analyte separation is achieved based on a chemical’s polarity and subsequent affinity to 
the stationary phase. For sample matrices in which analytes have very different affinities, 
isocratic elution can be used to achieve separation25. However, for screens containing analytes 
with similar polarities, a gradient elution is necessary for adequate separation. Gradient elutions 
are the most widely used HPLC method for WWBE, as researchers are often interested in a wide 
range of compounds. 
In a gradient elution the mobile phase is composed of a mixture of solvents that’s 
composition changes throughout the run, such as methanol and water25. During sample injection 
onto the column, the mobile phase is kept at a low elution strength, allowing analytes to become 
trapped by the stationary phase25. Once loaded, the gradient will change to begin eluting 
compounds with the least affinity toward the stationary phase first, followed by more strongly 
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retained analytes25. The time it takes for an analyte to move through the column is referred to as 
the compound’s retention time 25. Retention times are useful in determining if a suspected analyte 
is present but cannot be used for absolute identification, as multiple compounds can have the 
same or very similar retention times25.  
2.3.3 Tandem Mass Spectrometry 
 Mass spectrometry (MS) is an analysis technique used to identify chemicals according to 
their mass-to-charge ratios (m/z)26. This is achieved by ionizing compounds in their gaseous 
phase, typically by either adding (M+H+) or removing a proton (M-H+)24,26. Molecules are ionized 
so they can be easily manipulated by electrostatic and magnetic fields, allowing them to be 
isolated and measured24. Ions then enter the mass analyzer, a vacuum chamber containing four 
parallel metal rods in which radio frequency (RF) and direct current (DC) voltages are applied, 
called a quadrupole24,26. These RF and DC potentials are used to filter ions by their m/z, allowing 
only ions within a specific m/z range to reach the detector and produce a signal24,26.  
 Tandem mass spectrometry (MS/MS) is a form of multistage MS analysis that allows for 
better analyte identification24,26. The most common form of MS/MS used for WWBE is multiple 
reaction monitoring (MRM). In MRM, three mass analyzers are aligned in sequence with the first 
and last acting as mass filters and the central analyzer functioning as a collision cell24. The first 
quadrupole, Q1, functions just like a traditional MS, filtering ionized compounds by their m/z. 
These ions, referred to as precursor ions, then pass into the collision cell, Q2. The Q2 consists of 
a quadrupole, hexapole, octapole, or other design filled with an inert collision gas, typically argon 
or nitrogen24. Precursor ions collide with collision gas molecules and fragment into product ions 
with different m/z. The third analyzer, Q3, filters the product ions within a specified m/z range. 
MS/MS allows for more accurate analyte identification than traditional MS because precursor 
ions of similar m/z are not likely to fragment in exactly the same way, thus producing easily 
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identified product ions. Additionally, even if similar product ions are produced, the ratio in which 
they are produced is likely to be different for different precursor ions. For example, morphine and 
hydromorphone both have a m/z of 286 but morphine’s product ions are 165 and 152 whereas 
hydromorphone’s product ions are 184 and 157. Isolating these ions would be difficult on a 
traditional single quadrupole MS, but is far easier after fragmentation on MS/MS.  
2.4 Compounds of Interest 
 The LC-MS/MS method developed for this study screens for the following 56 drugs and 
metabolites: 6-monoacetylmorphine (6-MAM), 7-aminoclonazepam, 7-aminoflunitrazepam, α-
hydroxyalprazolam, α-hydroxytriazolam, alprazolam, amphetamine, benzoylecgonine, 
buprenorphine, carfentanil, carisoprodol, cocaine, codeine, cyclobenzaprine, desalkylflurazepam, 
diazepam, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), fentanyl, flunitrazepam, 
flurazepam, hydrocodone, hydromorphone, ketamine, lorazepam, MDMA, meperidine, 
meprobamate, methadone, methamphetamine, methylphenidate, midazolam, morphine, naloxone, 
naltrexone, norbuprenorphine, norcarfentanil, nordiazepam, norfentanyl, norhydrocodone, 
normeperidine, noroxycodone, O-desmethyltramadol, oxazepam, oxycodone, oxymorphone, 
phencyclidine (PCP), phentermine, propoxyphene, pseudoephedrine, sufentanil, tapentadol, 
temazepam, tramadol, trazodone, triazolam, and zolpidem. Δ⁹-Tetrahydrocannabinol (THC), and 
11-nor-9-carboxy-Δ⁹-THC (THCA) were originally included in the study but were not 
successfully extracted from wastewater and thus excluded in the final results.  
2.4.1 Opioids 
 Opioid is an overarching term referring to naturally occurring alkaloid analgesics derived 
from the opium poppy, semisynthetic alkaloids derived from naturally occurring opiates, and 
synthetic compounds that mimic the pharmacological effects of opiates24. The pharmacological 
effects of opioids are generally shared across all subclasses and impact the central nervous system 
10 
 
(CNS)24. While most opioids are used clinically for their analgesic effects, they have a high abuse 
potential due to their euphoric and sedative psychoactive effects24. Overdoses ending in death are 
often the result of respiratory failure24.  
Two of the three naturally occurring opiates, morphine and codeine, are included in this 
studies analysis panel in addition to the semisynthetic opioids hydrocodone, norhydrocodone, 
hydromorphone, oxycodone, noroxycodone, and oxymorphone27. 6-MAM, the metabolite of the 
semisynthetic opioid heroin has been reserved for the illicit section, 2.4.4, as the United States 
Drug Enforcement Agency (DEA) classifies it as a schedule I substance, meaning it has no 
accepted medical use28. The following synthetic opioids and their metabolites are also included in 
the panel: buprenorphine, norbuprenorphine, carfentanil, norcarfentanil, fentanyl, norfentanyl, 
sufentanil, methadone, EDDP, meperidine, normeperidine, naloxone, naltrexone, propoxyphene, 
tapentadol, tramadol, and O-desmethyltramadol.  
2.4.2 Benzodiazepines 
 Benzodiazepines are one of the most commonly prescribed drug classes in the United 
States and act as a CNS depressant24. First synthesized from an accidental reaction between 
quinazoline N-oxide and methylamine in the 1930’s, benzodiazepines were approved for clinical 
use by the FDA in 1960 and have largely replaced another CNS-depressant drug class, 
barbiturates, due to a reduced risk of adverse side effects and overdose24. One of the most 
common therapeutic uses of these drugs is as an anxiolytic, or to treat anxiety disorders24. The 
benzodiazepines included in this study are alprazolam, α-hydroxyalprazolam, 7-
aminoclonazepam, diazepam, nordiazepam, oxazepam, temazepam, flurazepam, lorazepam, 
midazolam, triazolam, and α-hydroxytriazolam. The benzodiazepine flunitrazepam and its 
metabolite are not included in this section since they are classified as schedule IV substances in 
the United Stated and will instead be discussed under section 2.4.428.  
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2.4.3 CNS Stimulants 
CNS stimulants, as the name would imply are compounds that bind to endogenous 
neurotransmitters to stimulate the central nervous system. CNS stimulants act through raising 
dopamine and norepinephrine levels within the body which elevates blood pressure, stimulates 
respiratory action, and at therapeutic doses raises the heart rate24,29. Many CNS stimulants have 
been identified as dangerous due to their potential for abuse and addiction due to their euphoric 
effects24. The most common cause of death by CNS stimulants are cardiac complications brought 
on by consumption of high doses24.  
The CNS stimulants of interest to this study are all amphetamines with the exception of 
methylphenidate, a drug commonly prescribed for attention deficit disorder under the brand name 
Ritalin. Cocaine, MDMA, and methamphetamine are also CNS stimulants of interest to this study 
but will be discussed in section 2.4.5 since MDMA is a schedule I substance and cocaine and 
methamphetamine are schedule II substances24,28. Amphetamine, phentermine, and 
pseudoephedrine (a decongestant and methamphetamine precursor) are the stimulants of interest 
to this study.  
2.4.4 Illicit Drugs 
For the purposes of this study, illicit drugs are compounds listed as schedule I controlled 
substances by the DEA or schedule II substances rarely used therapeutically such as cocaine, 
ketamine, and methamphetamine. The illicit substances of interest to this study are cocaine, 
flunitrazepam, ketamine, MDMA, methamphetamine, and PCP. The metabolite of the schedule I 
opioid heroin, 6-MAM, was included in this study while the parent compound was left out since it 
is typically quickly and entirely metabolized. The metabolites of cocaine (benzoylecgonine) and 




2.4.5 Miscellaneous Drugs 
 The miscellaneous drugs of interest to this study are compounds which do not fall under 
any of the other drug classes listed above. They include the muscle relaxants carisoprodol and 
cyclobenzaprine, the tricyclic antidepressant trazodone, and the hypnotic zolpidem. The 
metabolite of carisoprodol that is also sold as a drug, meprobamate, is also included in this study. 
The effects of each of these drugs is most similar to that of a benzodiazepine. 
2.5 Conclusion 
 The focus of this research is to develop a LC-MS/MS method for analyzing wastewater 
samples taken during football games. Specifically, the analysis method in question will screen for 
a panel of both prescription and illicit drugs and their metabolites from a wide range of drug 
classes. Previous studies have mainly focused on only one drug class or category at a time, 
developing relatively small analysis panels. Those studies which chose to screen for a large panel 
of substances did not apply them to special events. This study intends to provide a proof of 
concept for both the ability to detect numerous compounds in a single analysis and apply those 







3.1 Sampling Strategy 
Thirty-three (33) wastewater samples, listed in Table 1, were manually collected by the 
University of Florida (UF) collaborators during the football game between the Florida Gators and 
Kentucky Wildcats on Saturday, September 8, 2018 (game day population of 80,651). Samples 
were collected near the Ben Hill Griffith Stadium at three discrete locations to examine the 
variability in drug concentrations according to sub-populations (home, away, student, etc.) that 
attended the game. Samples per site were collected every half hour beginning approximately an 
hour before kickoff to 30 minutes after kickoff. Each sample was collected and placed into three 
different tubes: one 50 mL tube, and two 15 mL tubes. The continuous sampling strategy was 
designed to ensure comprehensive collection throughout the entire game, as well as enable the 
tracking of concentrations of drugs throughout the game. Four (4) additional samples were 
collected from the same locations and a wastewater station on Wednesday, September 5, 2018 to 
serve as background specimens. Once collected, samples were placed into a freezer for storage 
and mailed to the Oklahoma State University Forensic Toxicology and Trace Laboratory (OSU-
FTTL) for analysis.  
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Table 1. A complete list of the wastewater samples obtained by the University of Florida. Each sample was 
assigned a number for ease of reference. The date, time, and location of collection are listed in each column. The time 





Background 1 09/05/2018 Unknown University Ave 
Background 2 09/05/2018 Unknown Wastewater Station 
Background 3 09/05/2018 Unknown Pump Station 
Background 4 09/05/2018 Unknown Gale Lemerand Ave 
1 09/08/2018 6:30 University Ave 
2 09/08/2018 6:30 Pump Station 
3 09/08/2018 6:30 Gale Lemerand Ave 
4 09/08/2018 7:00 University Ave 
5 09/08/2018 7:00 Pump Station 
6 09/08/2018 7:00 Gale Lemerand Ave 
7 09/08/2018 7:30 University Ave 
8 09/08/2018 7:30 Pump Station 
9 09/08/2018 7:30 Gale Lemerand Ave 
10 09/08/2018 8:00 University Ave 
11 09/08/2018 8:00 Pump Station 
12 09/08/2018 8:00 Gale Lemerand Ave 
13 09/08/2018 8:30 University Ave 
14 09/08/2018 8:30 Pump Station 
15 09/08/2018 8:30 Gale Lemerand Ave 
16 09/08/2018 9:00 University Ave 
17 09/08/2018 9:00 Pump Station 
18 09/08/2018 9:00 Gale Lemerand Ave 
19 09/08/2018 9:30 University Ave 
20 09/08/2018 9:30 Pump Station 
21 09/08/2018 9:30 Gale Lemerand Ave 
22 09/08/2018 10:00 University Ave 
23 09/08/2018 10:00 Pump Station 
24 09/08/2018 10:00 Gale Lemerand Ave 
25 09/08/2018 10:30 University Ave 
26 09/08/2018 10:30 Pump Station 
27 09/08/2018 10:30 Gale Lemerand Ave 
28 09/08/2018 11:00 University Ave 
29 09/08/2018 11:00 Pump Station 
30 09/08/2018 11:00 Gale Lemerand Ave 
31 09/08/2018 11:30 University Ave 
32 09/08/2018 11:30 Pump Station 






3.2 Chemicals and reagents 
All materials were purchased from commercial suppliers except Nanopure water, which 
was obtained using a Barnstead Nanopure Diamond laboratory water system (Thermo Scientific, 
Waltham, MA). ACS-grade 37% hydrochloric acid was purchased from BDH (BDH Scientific, 
Radnor, PA).  LC-MS grade methanol and ACS-grade ammonium hydroxide were purchased 
from Fisher Scientific (Thermo Fisher Scientific, Waltham, MA). ACS-grade isopropyl alcohol 
was purchased from EM Science (EM Science, Gibbstown, NJ).  HPLC grade dichloromethane 
was purchased from VWR (VWR Analytical, Sugar Land, TX). HPLC grade 98% formic acid 
was purchased from EMD (EMD Millipore Corporation, Billerica, MA).  Crystalline ammonium 
formate (99%) was purchased from Alfa Aesar (Alfa Aesar, Ward Hill, MA). 
Drug standards at a concentration of 1 mg/mL in methanol were mostly purchased from 
Lipomed (Lipomed Inc, Cambridge, MA). EDDP, fentanyl, and norbuprenorphine drug stocks 
were also purchased from Lipomed at a concentration of 100 µg/mL. Methylphenidate and 
nordiazepam drug standards were purchased from Cerilliant (Cerilliant Corp, Round Rock, TX) at 
1 mg/mL and sufentanil was purchased from Cerilliant at 100 µg/mL in methanol.  Carfentanil 
and norcarfentanil were purchased from Cayman (Cayman Chemical, Ann Arbor, MI) at a 
concentration of 100 µg/mL in methanol. 7-Aminoclonazepam-D4, buorenorphine-D4, 
carisoprodol-D7, cocaine-D3, morphine-D6, nordiazepam-D5, and normeperidine-D4 deuterated 
internal standards were purchased from Cerilliant at a concentration of 1 mg/mL in methanol. All 
other deuterated internal standards were purchased from Cerilliant at a concentration of 100 






3.3 Solution Preparation 
 Separate calibration stock solution and quality control (QC) stock solution containing all 
of the analytes of interest at a concentration of 2500 ng/mL were prepared in methanol using the 
drug standards described in section 3.3. The details of this preparation are seen in Table 2. An 
additional internal standard stock solution containing 2500 ng/mL of each deuterated compound 
was prepared as seen in Table 3. All 3 stock solutions were created by spiking methanol with an 
aliquot of each certified drug standard.  
 
Table 2. Preparation for 2 mL of calibration and QC stock solution from certified drug standards. Spike volumes were 
calculated according to the µg/mL drug standard concentration in order to reach a final concentration of 2500 ng/mL.  






6-MAM 1000 5 2500 
7-Aminoclonazepam 1000 5 2500 
7-Aminoflunitrazepam 1000 5 2500 
A-Hydroxyalprazolam 1000 5 2500 
A-Hydroxytriazolam 1000 5 2500 
Alprazolam 1000 5 2500 
Amphetamine 1000 5 2500 
Benzoylecgonine 1000 5 2500 
Buprenorphine 1000 5 2500 
Carfentanil 100 50 2500 
Carisoprodol 1000 5 2500 
Cocaine 1000 5 2500 
Codeine 1000 5 2500 
Cyclobenzaprine 1000 5 2500 
Desalkylflurazepam 1000 5 2500 
Diazepam 1000 5 2500 
EDDP 100 50 2500 
Fentanyl 100 50 2500 
Flunitrazepam 1000 5 2500 
Flurazepam 1000 5 2500 
Hydrocodone 1000 5 2500 
Hydromorphone 1000 5 2500 
Ketamine 1000 5 2500 
Lorazepam 1000 5 2500 
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MDMA 1000 5 2500 
Meperidine 1000 5 2500 
Meprobamate 1000 5 2500 
Methadone 1000 5 2500 
Methamphetamine 1000 5 2500 
Methylphenidate 1000 5 2500 
Midazolam 1000 5 2500 
Morphine 1000 5 2500 
Naloxone 1000 5 2500 
Naltrexone 1000 5 2500 
Norbuprenorphine 100 50 2500 
Norcarfentanil 100 50 2500 
Nordiazepam 1000 5 2500 
Norfentanyl 1000 5 2500 
Norhydrocodone 1000 5 2500 
Normeperidine 100 50 2500 
Noroxycodone 1000 5 2500 
O-Desmethyltramadol 1000 5 2500 
Oxazepam 1000 5 2500 
Oxycodone 1000 5 2500 
Oxymorphone 1000 5 2500 
PCP 1000 5 2500 
Phentermine 1000 5 2500 
Propoxyphene 1000 5 2500 
R, R Pseudoephedrine 1000 5 2500 
Sufentanil 100 50 2500 
Tapentadol 1000 5 2500 
Temazepam 1000 5 2500 
THCA 1000 5 2500 
Tramadol 1000 5 2500 
Trazodone 1000 5 2500 
Triazolam 1000 5 2500 
Zolpidem 1000 5 2500 
THC 1000 5 2500 
 
Total Spike Volume (µL) = 605 
Methanol Volume (µL) = 1395 




Table 3. Preparation for 2 mL of deuterated internal standard stock solution from certified deuterated drug standards. 
Spike volumes were calculated according to the µg/mL internal standard concentration in order to reach a final 
concentration of 2500 ng/mL.  






7-Aminoclonazepam-D4 1000 5 2500 
7-Aminoflunitrazepam-D7 100 50 2500 
A-Hydroxytriazolam-D4 100 50 2500 
Amphetamine-D5 1000 5 2500 
Benzoylecgonine-D3 100 50 2500 
Buorenorphine-D4 1000 5 2500 
Carisoprodol-D7 1000 5 2500 
Cocaine-D3 100 50 2500 
Codeine-D6 1000 5 2500 
Cyclobenzaprine-D3 100 50 2500 
Diazepam-D5 100 50 2500 
Fentanyl-D5 100 50 2500 
Flunitrazepam-D7 100 50 2500 
Hydromorphone-D3 1000 5 2500 
Meperidine-D4 1000 5 2500 
Methadone-D3 1000 5 2500 
Methamphetamine-D5 1000 5 2500 
Methylphenidate-D9 100 50 2500 
Morphine-D6 1000 5 2500 
Nordiazepam-D5 1000 5 2500 
Normeperidine-D4 100 50 2500 
Oxycodone-D6 1000 5 2500 
PCP-D5 1000 5 2500 
Propoxyphene-D5 100 50 2500 
Pseudoephedrine-D3 1000 5 2500 
THCA-D3 1000 5 2500 
 
Total Spike Volume (µL) = 625 
Methanol Volume (µL) = 1375 
Total Solution Volume (µL) = 2000 
 
From the 2500 ng/mL calibration stock solution, eight (8) calibrators of the 
concentrations outlined in Table 4 were prepared in nanopure water via serial dilution using the 
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steps outlined in Table 5. 2 QCs were also prepared in a similar fashion using the 2500 ng/mL 
QC stock solution, outlined in Table 6.  
Table 4. Name and concentration of the 8 calibrators prepared via serial dilution from the 2500 ng/mL calibration 








































       
12896 13000 6470 
200c   6530             6530 13060 6515 
100c     6545           6545 13090 6505 
50c     
 
6585         6585 13170 6500 
25c         6670       6670 13340 6560 
15c           6780     4520 11300 6500 
10c             4800   2400 7200 6550 
1c               650 5850 6500 6500 
 















7485 7500 6525 





3.4 Solid phase extraction 
SPE was performed on the wastewater samples, the 8 calibrators, and a blank consisting 
only of nanopure water using a SPEware Cerex 48 positive pressure manifold and sample 
concentrator, seen in Figure 1 (Tecan SP, Inc., Baldwin Park, CA). Tecan Cerex Trace-B, 6mL 
columns, 50mg cartridges (Tecan SP, Inc., Baldwin Park, CA) were conditioned with 2 mL of 
methanol, followed by 2 mL of Nanopure water, and then 2 mL of pH 5 Nanopure water. Prior to 
loading each sample onto the SPE cartridge, 10 µL of internal standard mix and 25 µL of 100 
mM HCl was added to 6 mL of sample and the mixture was vortexed. Following sample addition, 
the SPE cartridges were washed twice with 2 mL of pH 5 Nanopure water. The cartridges were 
then dried under 70 psi nitrogen for 20 min. Following the drying step, 2 mL of an elution 
solution containing 80:18:2 (dichloromethane: isopropyl alcohol: ammonium hydroxide) was 
added to each cartridge twice and collected in a test tube. The elution mixtures were dried to 
complete dryness under a stream of nitrogen at 40 °C and reconstituted in 100 µL of 98% mobile 
phase A and 2% mobile phase B, the starting conditions of the LC gradient, before being 






Figure 1. A picture of the SPEware Cerex 48 positive pressure manifold and sample concentrator used to perform SPE 
on the wastewater samples. On the left is the positive pressure manifold used to applying nitrogen gas for loading 
samples and drying the SPE cartridge sorbent. On the right is the sample concentrator used to accelerate the 




Table 7. Outline of the solid phase extraction procedure. 
SPE Step Parameter 
Sample Preparation 6 mL wastewater 
 10 L 2500 ng/mL internal standard mix 
  25 L 100mM HCl 
Condition 2 mL LC-MS grade methanol 
  
2 mL Nanopure water 
2 mL pH 5 Nanopure water 
Sample Addition 6.035 mL sample 
Rinse 2 x 2 mL pH 5 Nanopure water 
Cartridge Dry Down 20 min at ~70 psi 
Elution 2 x 2 mL 80:18:2 dichloromethane:isopropanol:ammonium hydroxide 
Elution Dry Down Under nitrogen at 40ºC 
Reconstitution 100 L 98:2 mobile phase A:mobile phase B 
 
3.5 LC-MS/MS Analysis 
 The 4 background samples were extracted and analyzed once due to the sample volume 
available, while the other 33 samples were extracted on two separate occasions. The first 
extraction was analyzed on a Waters Acquity Classic UPLC-MS/MS system. During this initial 
analysis a number of QCs and calibrators were observed outside of acceptable parameters, and 
therefore the analysis was repeated on the Waters system, with similar results. These samples 
were then moved to a Shimadzu UFLC-MS/MS system in the OSU-FTTL for further analysis in 
order to rule out issues specifically related to the Waters method.  
 
3.5.1 Waters Acquity Classic UPLC-MS/MS 
Initially a method for instrumental analysis on a Waters Acquity Classic UPLC-MS/MS 
system, seen in Figure 2, was developed for this project. Separation was achieved using a Waters 
Cortecs C18 HPLC column (2.1 x 100 mm; 2.7 um; 90 Å) with an Acquity UPLC BEH C18 1.7 
µm guard cartridge (2.1 x 5mm) attached (Waters Corporation, Milford, MA). Mobile phase A 
consisted of 10mM ammonium formate and 0.1% formic acid in water and mobile phase B 
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consisted of 10 mM ammonium formate and 0.1% formic acid in methanol. The LC pumps were 
held at a flow rate of 0.400 mL/min and column temperature was maintained at 65 °C. Sample 
injections were set at 10 μL. LC-MS/MS methods were developed and chromatograms were 
observed using Mass Lynx (Waters Corporation, Milford, MA). Analyte quantification was done 
using Target Lynx (Waters Corporation, Milford, MA). 
 
 
Figure 2. A picture of the Waters Acquity Classic UPLC-MS/MS system used to analyze the wastewater samples in 
this study. On the right are the UPLC pumps, autosampler, and column oven. On the left is the tandem quadrupole 
detector (TQD). 
 
The gradient program used for chromatographic separation of the compounds of interest, 
visualized graphically in Figure 3, began at 2% mobile phase B and was maintained at 2% for 
1.25 min before increasing to 20% in 3.75 min. The mobile phase B concentration was then 
increased to 50% in 4 min, followed by a further increase to 90% mobile phase B in 1 min. The 
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gradient was then held at 90% for 0.5 minutes before being returned to 10% mobile phase B in 
1.5 min. The gradient was further decreased to 2% mobile phase B in 0.01 min and held for the 
last minute, resulting in a total run time of 13 minutes.  
 
 
Figure 3. A plot of the chromatographic gradient used to separate the compounds of interest presented as percentage of 
each mobile phase over time. The yellow color represents mobile phase A while the blue represents mobile phase B.  
 
MRM ion transitions and parameters were optimized using Mass Lynx Intellistart.  These 
parameters are summarized in Table 8 for the compounds of interest and Table 9 for the 
deuterated internal standards. Compound identity was confirmed by use of an MRM ratio, which 
compared the MRM transition with a smaller peak area to the MRM transition with a larger peak 
area.  An acceptable range for the MRM ratio was calculated by averaging the MRM ratios of 
each calibrator for a given compound. The MRM ratios had to be within 20% of this averaged 
MRM ratio. Identification was further established by relative retention times. Relative retention 
times were defined as the retention time of a compound of interest divided by the retention time 
of said compound’s internal standard. As with the MRM ratios, an acceptable range was 
determined by averaging the relative retention times of the calibrators for a given compound; all 





Table 8. Retention times, MRM transitions, and optimized mass spectrometer parameters used to analyze for 
compounds of interest on the Waters Acquity Classic UPLC-MS/MS.  For each compound, the quantitative MRM 
transition is on the top row and the qualitative MRM transition is on the second row. 










6-MAM 4.39 328.16 165.01 36 17 
 328.16 57.97 30 17 
7-Aminoclonazepam 5.92 286.04 120.97 28 50 
 286.04 222.03 24 50 
7-Aminoflunitrazepam 6.90 284.08 135.11 30 48 
 284.08 226.39 34 48 
Alpha-Hydroxyalprazolam 9.62 325.03 297.19 24 51 
 325.03 216.05 40 51 
Alpha-Hydroxytriazolam 9.54 359.07 176.09 26 54 
 359.07 331.04 28 54 
Alprazolam 9.95 308.97 281.02 26 31 
 308.97 204.93 40 31 
Amphetamine 3.81 135.95 91.10 16 22 
 135.95 119.13 10 22 
Benzoylecgonine 5.39 290.23 168.10 18 39 
 290.23 105.02 28 39 
Buprenorphine 9.22 468.29 54.98 52 44 
 468.29 83.79 44 44 
Carfentanil 8.57 395.40 113.09 32 32 
 395.40 335.25 18 32 
Carisoprodol 9.90 261.17 176.12 8 24 
 261.17 55.04 26 24 
Cocaine 6.42 304.10 182.04 18 35 
 304.10 81.97 28 35 
Codeine 3.57 300.00 165.00 38 49 
 300.00 215.03 26 49 
Cyclobenzaprine 9.54 276.14 84.14 26 40 
 276.14 58.12 20 40 
Desalkylflurazepam 10.03 289.02 140.05 32 52 
 289.02 226.13 30 52 
Diazepam 10.32 285.26 154.06 26 48 
 285.26 193.15 30 48 
EDDP 8.51 278.28 234.11 30 56 
 278.28 249.07 24 56 
Fentanyl 8.17 337.19 105.13 40 46 
 337.19 188.23 24 46 
Flunitrazepam 9.43 314.05 268.21 28 48 
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 314.05 239.21 40 48 
Flurazepam 8.63 388.18 315.16 26 40 
 388.18 100.13 28 40 
Hydrocodone 4.06 300.10 198.97 28 53 
 300.10 127.95 52 53 
Hydromorphone 2.00 286.10 184.97 30 55 
 286.10 157.01 44 55 
Ketamine 5.90 238.06 125.03 28 32 
 238.06 220.16 16 32 
Lorazepam 9.90 321.04 275.00 20 38 
 321.04 229.03 28 38 
MDMA 4.34 194.02 163.10 12 26 
 194.02 105.09 20 26 
Meperidine 6.94 248.13 70.03 32 46 
 248.13 174.16 24 46 
Meprobamate 7.51 219.28 158.17 8 20 
 219.28 55.06 24 20 
Methadone 9.82 310.48 265.27 16 8 
 310.48 105.08 28 8 
Methamphetamine 4.22 150.26 91.05 18 18 
 150.26 119.09 10 18 
Methylphenidate 6.56 234.11 84.13 22 34 
 234.11 56.04 50 34 
Midazolam 9.17 326.05 291.12 28 54 
 326.05 249.25 40 54 
Morphine 1.34 286.11 165.15 38 52 
 286.11 152.22 66 52 
Naloxone 3.57 328.18 310.23 20 40 
 328.18 212.17 42 40 
Naltrexone 4.09 342.20 324.18 22 42 
 342.20 55.06 44 42 
Norbuprenorphine 7.90 414.29 83.09 50 64 
 414.29 57.14 48 64 
Norcarfentanil 6.77 291.27 113.09 28 28 
 291.27 231.22 16 28 
Nordiazepam 10.20 271.03 139.92 28 49 
 271.03 90.95 36 49 
Norfentanyl 6.05 233.36 84.09 18 30 
 233.36 55.32 34 30 
Norhydrocodone 4.11 286.08 199.01 28 38 
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 286.08 127.94 52 38 
Normeperidine 7.12 234.05 160.16 18 36 
 234.05 42.06 32 36 
Noroxycodone 3.89 302.14 186.98 22 40 
 302.14 226.97 30 40 
O-Desmethyltramadol 4.58 250.14 58.06 18 26 
 250.14 42.22 60 26 
Oxazepam 9.81 286.97 241.00 20 35 
 286.97 103.94 34 35 
Oxycodone 3.88 316.16 241.07 28 35 
 316.16 256.03 24 35 
Oxymorphone 1.58 302.10 226.99 26 43 
 302.10 198.05 46 43 
PCP 7.71 244.17 86.14 10 22 
 244.17 91.09 30 22 
Phentermine 5.15 149.96 91.05 22 18 
 149.96 133.14 10 18 
Propoxyphene 9.66 340.19 58.12 16 20 
 340.19 266.26 8 20 
Pseudoephedrine 3.42 166.26 148.11 14 22 
 166.26 117.08 20 22 
Sufentanil 9.27 387.24 238.16 20 36 
 387.24 111.05 40 36 
9-THC 11.16 315.43 123.10 32 36 
 315.43 193.22 24 36 
11-nor-9-carboxy-9-THC 10.84 345.41 327.32 16 38 
 345.41 299.29 20 38 
Tapentadol 6.63 222.20 106.94 26 30 
 222.20 120.93 22 30 
Temazepam 10.06 301.03 254.94 20 35 
 301.03 176.97 36 35 
Tramadol 6.40 264.16 58.12 18 28 
 264.16 264.16 10 28 
Trazodone 7.61 372.18 176.14 26 46 
 372.18 148.12 38 46 
Triazolam 9.98 343.01 308.15 28 54 
 343.01 239.04 48 54 
Zolpidem 7.29 308.14 235.24 40 54 




Table 9. Retention times, MRM transitions, and optimized mass spectrometer parameters for the deuterated internal 
standards. 










7-Aminoclonazepam-D6 5.87 290.16 121.00 32 50 
7-Aminoflunitrazepam-D7 6.83 291.20 138.08 30 50 
Alpha-Hydroxytriazolam-D4 9.51 363.04 176.09 30 52 
Amphetamine-D5 3.76 141.03 124.15 8 24 
Benzoylecgonine-D3 5.38 293.14 171.14 22 38 
Buprenorphine-D4 9.15 472.35 59.01 50 67 
Carisoprodol-D7 9.88 268.40 183.25 10 18 
Cocaine-D3 6.42 307.10 185.04 20 39 
Codeine-D6 3.53 306.20 61.11 34 54 
Cyclobenzaprine-D3 9.54 279.18 216.03 26 40 
Diazepam-D5 10.31 290.29 198.17 32 42 
Fentanyl-D5 8.14 342.29 104.98 38 49 
Flunitrazepam-D7 9.38 321.06 275.22 30 50 
Hydromorphone-D3 1.97 289.16 184.98 30 57 
Meperidine-D4 6.92 252.16 224.25 22 42 
Methadone-D3 9.80 313.43 105.09 26 44 
Methamphetamine-D5 4.19 155.05 91.94 18 26 
Methylphenidate-D9 6.52 243.17 93.18 24 32 
Morphine-D6 1.32 292.12 152.29 64 52 
Nordiazepam-D5 10.19 276.16 140.16 24 61 
Normeperidine-D4 7.11 238.08 164.19 18 38 
Oxycodone-D6 3.85 322.13 304.31 20 42 
PCP-D5 7.67 249.19 86.15 24 24 
Propoxyphene-D5 9.63 345.21 58.12 14 20 
Pseudoephedrine-D3 3.40 169.26 151.18 12 20 
11-nor-9-carboxy-9-THC-D3 10.83 348.36 330.28 16 30 
 
3.5.2 Shimadzu 8040 UFLC-MS/MS 
Due to inconsistencies observed during analysis using the Waters UPLC-MS/MS, the 
second extraction was also analyzed on a Shimadzu 8040 UFLC-MS/MS, seen in Figure 4 
(Shimadzu Corporation, Kyoto, Japan). Chromatographic separation was achieved using a Restek 
Raptor Biphenyl 2.7 µm column (50 x 2.1 mm) with a Raptor Biphenyl 2.7 µm guard cartridge (5 
x 3.0 mm) attached to it (Restek Corporation, Bellefonte, PA). Mobile phase A consisted of 2 
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mM ammonium formate and 0.1% formic acid in water, while mobile phase B consisted of 2 mM 
ammonium formate and 0.1% formic acid in methanol. The LC pumps were held at a flow rate of 
0.350 mL/min during analysis and raised to 0.500 mL/min for 1 minute between injections. The 
column oven was set to 30 °C during analysis and sample injections were set at 10 μL. This LC-
MS/MS method was developed and validated by OSU-FTTL for clinical urine analysis. 
 The gradient program used for chromatographic separation of analytes began at a 
concentration of 10% mobile phase B and was increased to 35% over 1.40 min. The 
concentration of mobile phase B was further increased to 100% over 1.50 min and held at this 
concentration for another 1.00 min. The concentration was then returned to 10% in 0.01 min and 
maintained at this concentration until the next injection, for a total run time of 5 minutes. 
 
Figure 4. A picture of the Shimadzu 8040 UFLC-MS/MS system used to analyze the wastewater samples in this study. 
On the left are the UFLC pumps, autosampler, communications bus module, UV-VIS detector, and column oven. On 
the right is the tandem mass spectrometer. 
 
 The MRM ion transitions used for analyte identification and quantification are 
summarized in Table 10 for the compounds of interest and Table 11 for the deuterated internal 
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standards. Compound identity was confirmed by use of the same parameters as the Waters 
Acquity Classic, described in section 3.5.1.  
 
Table 10. Retention times, MRM transitions, and optimized mass spectrometer parameters used to analyze for 
compounds of interest on the Shimadzu 8040 UFLC-MS/MS.  For each compound, the quantitative MRM transition is 
on the top row and the qualitative MRM transition is on the second row. 
 












6-MAM 2.38 328.20 165.05 -10 -40 -30 
  
328.20 58.10 -10 -29 -20 
7-Aminoclonazepam 2.98 286.00 121.10 -45 -32 -45 
  
286.00 222.10 -45 -24 -45 
Alpha-Hydroxyalprazolam 3.49 324.90 297.05 -16 -27 -32 
  
324.90 216.00 -16 -42 -42 
Alprazolam 3.62 309.30 281.00 -20 -27 -30 
  
309.30 205.00 -20 -45 -38 
Amphetamine 1.88 136.00 91.10 -20 -17 -15 
  
136.00 119.15 -20 -14 -45 
Benzoylecgonine 2.89 289.95 168.05 -14 -19 -30 
  
289.95 104.95 -20 -29 -18 
Buprenorphine 3.12 468.10 55.10 -30 -55 -20 
  
468.30 84.05 -30 -49 -30 
Carisoprodol 3.15 261.00 176.00 -30 -8 -18 
  
261.20 55.05 -28 -30 -20 
Clonazepam 3.43 316.20 270.00 -50 -35 -30 
  
316.20 214.00 -50 -35 -45 
Codeine 2.35 299.90 165.00 -35 -43 -30 
  
299.90 215.00 -35 -28 -20 
Desipramine 3.25 267.00 44.10 -30 -35 -46 
  
267.00 72.15 -42 -25 -28 
Diazepam 3.71 284.90 153.95 -36 -28 -28 
  
284.90 193.00 -46 -34 -34 
EDDP 3.24 278.10 234.00 -15 -32 -45 
  
278.10 249.05 -35 -23 -25 
Fentanyl 3.13 337.25 188.10 -22 -24 -18 
  
337.25 105.10 -22 -39 -38 
Hydrocodone 2.58 299.90 199.00 -35 -40 -35 
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Bias (V)   
300.30 171.10 -50 -40 -30 
Hydromorphone 1.79 285.90 185.00 -32 -32 -34 
  
285.90 157.00 -32 -42 -26 
JWH-018 Metabolite 3.70 358.00 154.95 -18 -25 -28 
  
358.00 126.95 -18 -52 -48 
JWH-073 Metabolite 3.64 343.90 154.95 -40 -35 -28 
  
344.40 126.95 -12 -40 -48 
Ketamine 2.89 238.20 125.00 -40 -27 -45 
  
238.20 207.10 -40 -14 -20 
Lorazepam 3.36 320.80 274.90 -40 -23 -50 
  
320.80 229.00 -40 -30 -45 
MDMA 2.47 194.05 163.10 -30 -14 -30 
  
194.05 105.05 -30 -26 -40 
Meperidine 2.90 247.80 174.00 -44 -19 -32 
  
247.80 70.05 -40 -29 -26 
Meprobamate 2.92 218.90 55.00 -24 -24 -20 
  
218.90 97.05 -24 -15 -36 
Methadone 3.37 309.85 265.10 -40 -25 -28 
  
309.85 105.00 -36 -28 -38 
Methamphetamine 2.20 149.75 91.00 -16 -10 -16 
  
149.75 119.05 -16 -15 -44 
Morphine 1.57 286.10 165.00 -45 -42 -30 
  
286.10 155.10 -45 -35 -15 
Norbuprenorphine 2.99 414.30 83.10 -25 -54 -15 
  
414.30 101.20 -25 -40 -40 
Nordiazepam 3.52 271.20 139.90 -18 -29 -24 
  
271.20 208.10 -18 -30 -40 
Norfentanyl 2.71 233.10 84.05 -40 -19 -30 
  
233.10 55.05 -15 -35 -20 
Norhydrocodone 2.38 285.90 198.95 -32 -30 -36 
  
286.00 127.95 -14 -55 -46 
Normeperidine 2.89 233.80 160.00 -26 -16 -28 
  
233.90 42.10 -26 -32 -14 
Noroxycodone 2.29 302.10 187.00 -20 -26 -35 
  
302.10 227.00 -20 -31 -45 
Nortriptyline 3.28 263.85 233.05 -50 -14 -24 
  
263.85 91.10 -50 -24 -36 
Oxazepam 3.42 287.20 241.00 -50 -23 -25 
  
287.20 104.00 -15 -34 -40 
Oxycodone 2.54 315.70 298.15 -35 -19 -30 
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Bias (V)   
315.90 241.10 -40 -31 -50 
Oxymorphone 1.64 301.90 227.00 -34 -30 -40 
  
301.90 198.00 -34 -48 -36 
PCP 3.16 243.85 86.05 -44 -11 -14 
  
243.85 158.95 -44 -13 -28 
Propoxyphene 3.15 340.40 266.20 -10 -17 -30 
  
266.30 58.00 -45 -14 -20 
Tapentadol 2.77 222.10 107.05 -30 -27 -40 
  
222.10 121.05 -35 -21 -20 
Temazepam 3.59 301.10 255.00 -20 -40 -25 
  
301.20 176.90 -20 -40 -30 
THCA 3.68 345.10 299.10 -20 -20 -20 
  
345.10 192.90 -40 -27 -35 
Tramadol 2.82 263.60 264.10 -30 -7 -30 
  
264.20 58.05 -10 -10 -20 
 
 
Table 11. Retention times, MRM transitions, and optimized mass spectrometer parameters for the deuterated internal 
standards on the Shimadzu 8040 UFLC-MS/MS. For each compound, the quantitative MRM transition is on the top 
row and the qualitative MRM transition is on the second row. 












7-Aminoclonazepam-D4 2.97 289.90 121.00 -34 -31 -46 
  
289.90 226.00 -34 -26 -42 
Amphetamine-D5 1.85 140.80 93.00 -15 -19 -35 
  
140.80 66.00 -15 -40 -25 
Benzoylecgonine-D3 2.89 292.80 171.05 -38 -19 -30 
  
292.80 105.00 -38 -33 -40 
Codeine-D6 2.33 305.90 165.10 -40 -45 -30 
  
306.10 218.10 -15 -26 -45 
Desipramine-D3 3.25 269.80 75.10 -32 -16 -28 
  
269.80 47.05 -32 -40 -50 
Diazepam-D5 3.71 289.90 153.95 -50 -29 -28 
  
289.90 227.10 -50 -28 -24 
Fentanyl-D5 3.13 341.85 105.10 -46 -42 -38 
  
341.85 137.10 -46 -35 -50 
Hydromorphone-D3 1.79 288.90 184.95 -50 -31 -34 
  
288.90 156.95 -50 -44 -28 
JWH-018 Metabolite-D5 3.69 363.60 155.00 -26 -24 -28 
33 
 











Bias (V)   
363.60 127.00 -26 -52 -48 
Meperidine-D4 2.89 251.80 224.10 -42 -22 -22 
  
251.80 178.05 -42 -20 -32 
Methadone-D3 3.33 312.85 268.15 -48 -15 -28 
  
312.85 104.95 -48 -30 -42 
Methamphetamine-D5 2.18 154.95 92.10 -16 -20 -34 
  
154.90 66.10 -16 -42 -24 
Morphine-D6 1.55 292.20 152.00 -20 -54 -50 
  
292.20 181.10 -20 -38 -35 
Normeperidine-D4 2.89 238.00 164.10 -12 -16 -16 
  
238.00 42.05 -12 -35 -44 
Nortryptyline-D3 3.27 266.95 233.10 -50 -15 -24 
  
266.95 91.00 -50 -24 -34 
Oxycodone-D6 2.53 321.90 304.15 -38 -20 -32 
  
321.90 247.10 -38 -33 -42 
PCP-D5 3.15 248.85 86.10 -30 -12 -34 
  
248.85 96.00 -30 -32 -34 
Propoxyphene-D5 3.15 345.10 58.15 -22 -23 -22 
  
345.10 271.20 -22 -10 -18 
THC-D3 3.70 348.10 331.00 -20 -8 -35 
  
348.10 313.00 -50 -12 -30 
 
3.5.3 LC-MS/MS Lower Limit of Quantitation 
The lower limit of quantitation (LLOQ) for each compound of interest varied between analyses 
when using Waters UPLC-MS/MS method. The first set of wastewater samples, calibration 
curve, QCs, and blank was only analyzed on the Waters. The second set of extracted samples, 
calibrators, QCs, and blank was analyzed on both the Waters and Shimadzu. The LLOQ 
concentrations for each analysis are given in Table 12. 
Table 12. LLOQ Concentrations for each analyte of interest across the 3 different wastewater analyses. 
Analyte Name 1st Waters Analysis 
LLOQ (ng/mL) 
2nd Waters Analysis 
LLOQ (ng/mL) 
 Shimadzu Analysis 
LLOQ (ng/mL) 
6-MAM 0.05 0.05 0.05 
7-Aminoclonazepam 0.05 0.05 0.05 
7-Aminoflunitrazepam 0.05 0.05 N/A 
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Analyte Name 1st Waters Analysis 
LLOQ (ng/mL) 
2nd Waters Analysis 
LLOQ (ng/mL) 
 Shimadzu Analysis 
LLOQ (ng/mL) 
α-Hydroxyalprazolam 0.05 0.05 0.05 
α-Hydroxytriazolam 0.05 0.05 N/A 
Alprazolam 0.05 0.05 0.05 
Amphetamine 0.5 0.05 0.05 
Benzoylecgonine 0.05 0.05 0.05 
Buprenorphine 0.05 0.75 0.75 
Carfentanil 0.05 0.75 N/A 
Carisoprodol 0.5 0.05 0.05 
Cocaine 0.05 0.15* N/A 
Codeine 0.05 0.05 0.05 
Cyclobenzaprine 0.5 1.25 N/A 
Desalkylflurazepam 0.5 0.05 N/A 
Diazepam 0.05 0.05 0.05 
EDDP 0.05 0.75 0.75 
Fentanyl 0.05 0.5 0.5 
Flunitrazepam 0.05 0.05 N/A 
Flurazepam 0.05 1.25 N/A 
Hydrocodone 0.05 0.05 0.05 
Hydromorphone 0.05 0.5 0.05 
Ketamine 0.05 0.05 0.05 
Lorazepam 0.05 0.05 0.5 
MDMA 0.05 0.05 0.05 
Meperidine 0.05 0.5 0.5 
Meprobamate 0.5 0.5 0.5 
Methadone 0.5 2.5 2.5 
Methamphetamine 0.5 0.15* 0.5* 
Methylphenidate 0.05 0.05 N/A 
Midazolam 0.05 0.5 N/A 
Morphine 0.05 0.05 0.05 
Naloxone 0.05 0.05 N/A 
Naltrexone 0.05 0.05 N/A 
Norbuprenorphine 0.05 0.05 0.5 
Norcarfentanil 0.05 0.05 N/A 
Nordiazepam 0.05 0.05 0.05 
Norfentanyl 0.05 0.05 0.05 
Norhydrocodone 0.05 0.05 0.05 
Normeperidine 0.05 0.5 0.5 
Noroxycodone 0.05 0.05 0.05 
O-Desmethyltramadol 0.5 0.05 N/A 
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Analyte Name 1st Waters Analysis 
LLOQ (ng/mL) 
2nd Waters Analysis 
LLOQ (ng/mL) 
 Shimadzu Analysis 
LLOQ (ng/mL) 
Oxazepam 0.05 0.05 0.5 
Oxycodone 0.5 0.05 0.05 
Oxymorphone 0.05 0.05 0.05 
PCP 0.05 0.5 0.5 
Phentermine 0.05 0.05 N/A 
Propoxyphene 0.05 0.5 0.5 
Pseudoephedrine 0.05 0.05 N/A 
Sufentanil 0.05 0.5 N/A 
Tapentadol 0.05 0.05 0.5 
Temazepam 0.05 0.05 0.05 
Tramadol 0.05 0.05 0.5 
Trazodone 0.05 0.5 N/A 
Triazolam 0.05 0.5 N/A 
Zolpidem 0.05 0.5 N/A 
  
* LLOQ between 1c (0.05 ng/mL) and 10c (0.5 ng/mL) calibrators due to analyte contamination observed in the blank. 
 
3.6 Summary 
 Wastewater samples collected by UF were extracted via SPE and analyzed at OSU-FTTL 
using two different LC-MS/MS systems. If a compound of interest was able to be quantified 
above the lowest calibrator, lower limit of quantitation (LLOQ), and was within a 20% range of 







4.1 LC-MS/MS Results 
 Concentrations of the compounds of interest were obtained using the methods described 
in Chapter III. The results each LC-MS/MS analysis are summarized in their own subsections for 
clarity.  
4.1.1 Initial Extraction Analysis on the Waters UPLC-MS/MS 
 The results of the 4 background samples obtained on September 5, 2018 are given in 
Table 13. The results of the first batch of samples extracted and analyzed on the Waters system 
are given in Table 14.  
Table 13. Concentrations of compounds observed in the 4 background waste water samples collected before the UF 
game. Compounds that were not observed as being present in any of the samples were removed from the table for 
clarity. Concentrations are reported in ng/mL.  
Compound Name Background 1 Background 2 Background 3 Background 4 
Benzoylecgonine 0.2 0.3 - 0.3 
Cocaine - 0.1 - - 
Ketamine - - - 0.1 
Morphine - 0.1 - 0.1 
Phentermine - - - 0.2 
Pseudoephedrine - 0.4 0.2 1.2 
Tramadol - 0.1 - 0.2 
Trazodone - - 0.1 0.1 
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Table 14. Concentrations of compounds observed in the initially extracted 33 wastewater samples collected during the 
game. Compounds that were not observed as being present in any of the samples were removed from the table for 
clarity. Concentrations are reported in ng/mL.  
Sample # 7-Aminoclonazepam Amphetamine Benzoylecgonine Cocaine 
1 * †† 0.8 0.3 
2 - †† 1.9 0.4 
3 - †† 2.0 1.9 
4 - 0.7 0.8 0.7 
5 - †† 6.3 1.8 
6 - 1.0 0.8 0.4 
7 - †† 2.1 1.3 
8 - 1.0 2.0 0.4 
9 - 5.2 1.0 1.2 
10 - * 3.9 5.0 
11 - 1.1 1.9 1.1 
12 - †† 2.5 2.2 
13 - 0.7 1.3 1.2 
14 - 3.5 2.0 1.0 
15 - 4.6 7.2 5.1 
16 - 4.2 20 0.9 
17 - 0.8 1.8 1.2 
18 - 1.5 2.1 0.9 
19 - 0.8 4.0 1.1 
20 - 4.0 5.9 0.8 
21 - 2.4 3.7 2.2 
22 - 2.1 0.5 0.6 
23 - 5.2 0.5 0.5 
24 - †† 0.9 2.3 
25 - †† 3.1 10 
26 - 1.9 0.1 0.1 
27 † † † † 
28 - 2.3 0.1 0.1 
29 - †† 0.6 0.2 
30 - †† 10 2.6 
31 - 3.7 * - 
32 - †† 0.2 0.1 
33 - †† 0.3 0.7 
* Detected below the lower limit of quantitation, ** Detected outside the allowed 20% ratio range, *** 
Detected below the lower limit of quantitation and outside of 20% ratio range, † Sample 27 Omitted due to 
suspected contamination, †† No quantitative data available due to nearby unknown interfering peak resulting 
in a ratio outside of the 20% range 
 
Table 14. (continued) 
Sample # Codeine Cyclobenzaprine EDDP Hydrocodone 
1 - - - 0.2 
2 - - - 0.2 
3 - 0.6 - 0.1 
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4 - - - * 
5 * - - - 
6 - - - 0.1 
7 - - - - 
8 - - 0.3 0.1 
9 0.3 - - 0.1 
10 - - - - 
11 - - - 0.1 
12 - - - *  
13 - - 0.1 - 
14 * - - 0.1 
15 - - - - 
16 - - - - 
17 - - - 0.1 
18 - - - - 
19 *** - - - 
20 *** - - 0.6 
21 - - - 0.6 
22 - - - 0.2 
23 - - - 0.3 
24 - - - 0.1 
25 0.2 - - * 
26 - - 0.1 0.2 
27 † † † † 
28 - - - - 
29 0.2 - - 0.1 
30 - - - 0.2 
31 - - - 0.1 
32 - - - 0.2 
33 - - - - 
* Detected below the lower limit of quantitation 
** Detected outside the allowed 20% ratio range 
*** Detected below the lower limit of quantitation and outside of 20% ratio range 
† Sample 27 Omitted due to suspected contamination 






Table 14. (continued) 
Sample # Hydromorphone Ketamine MDMA Methadone 
1 - - - - 
2 - - - - 
3 - - - - 
4 - - - - 
5 - - - - 
6 - - - - 
7 - - - - 
8 * 0.3 - 1.1 
9 - - - - 
10 - - - - 
11 - - - - 
12 - - - - 
13 - - - - 
14 - - 0.1 - 
15 - - - - 
16 - - - - 
17 - - - - 
18 - - - - 
19 - - - - 
20 * - - - 
21 - - - - 
22 - - - - 
23 - 0.3 2.6 - 
24 - - - - 
25 - - - - 
26 - - 0.1 - 
27 † † † † 
28 - - - - 
29 - - - - 
30 - - - - 
31 - - - - 
32 - - - - 
33 - - - - 
* Detected below the lower limit of quantitation 
** Detected outside the allowed 20% ratio range 
*** Detected below the lower limit of quantitation and outside of 20% ratio range 
† Sample 27 Omitted due to suspected contamination 






Table 14. (continued) 
Sample # Methamphetamine Methylphenidate Morphine Norhydrocodone 
1 - - - 0.3 
2 - - - 0.1 
3 - - 0.3 0.1 
4 - - - - 
5 * - - - 
6 1.1 * - 0.1 
7 - - - - 
8 - - * 0.1 
9 - - - - 
10 - 0.1 - - 
11 * - - 0.1** 
12 - - - - 
13 - - - - 
14 * - - 0.2 
15 - - - - 
16 - - - - 
17 - - - 0.1 
18 - - - - 
19 - - - - 
20 - - 0.1 0.5 
21 - - - 0.3 
22 - - - 0.1 
23 - - 0.1 0.3 
24 - - - 0.1 
25 - - - - 
26 - - - 0.2 
27 † † † † 
28 - - - - 
29 - - - 0.1 
30 - - - 0.1 
31 - - - 0.1 
32 - - - 0.1 
33 - - - - 
* Detected below the lower limit of quantitation 
** Detected outside the allowed 20% ratio range 
*** Detected below the lower limit of quantitation and outside of 20% ratio range 
† Sample 27 Omitted due to suspected contamination 






Table 14. (continued) 
Sample # Noroxycodone O-Desmethyltramadol Oxycodone Oxymorphone 
1 0.1 - * - 
2 0.3 - * * 
3 0.2 0.9 * * 
4 - - - - 
5 0.1 - * * 
6 0.1 0.7 * - 
7 - 0.3 * - 
8 - - - - 
9 - - * - 
10 - - - - 
11 - - - - 
12 0.2 - * - 
13 2.6 4.5 * - 
14 0.3 1.7 * * 
15 0.5 0.6 * - 
16 - - - - 
17 1.0 - * * 
18 0.1** - * - 
19 - - - - 
20 0.7 - * * 
21 0.3 - * - 
22 - - - - 
23 0.2 - * - 
24 0.1 0.6** * - 
25 - 1.4 - - 
26 0.1 - - - 
27 † † † † 
28 - - - - 
29 0.1 0.6 * - 
30 0.2 1.7 * - 
31 - - - - 
32 * - * - 
33 0.3 - *** - 
* Detected below the lower limit of quantitation 
** Detected outside the allowed 20% ratio range 
*** Detected below the lower limit of quantitation and outside of 20% ratio range 
† Sample 27 Omitted due to suspected contamination 






Table 14. (continued) 
Sample # Phentermine Pseudoephedrine Tapentadol Temazepam 
1 0.5 10 - - 
2 0.7 24 - - 
3 4.8 9.6 1.5 0.2 
4 0.3 2.4 - - 
5 2.2 2.5 - - 
6 0.3 4.5 - - 
7 1.3 6.0 - - 
8 0.1 3.1 - *** 
9 2.5 19 0.4 * 
10 0.9 8.0 - - 
11 * 9.1 - - 
12 0.2 14 - - 
13 - 7.2 - - 
14 1.1 9.3 - * 
15 3.5 19 - - 
16 4.9 10 - - 
17 - 8.8 - * 
18 4.6 4.5 - - 
19 1.5 36 - - 
20 1.8 14 - *** 
21 0.1 27 - - 
22 1.8 1.4 - - 
23 3.6 17 - * 
24 1.4 74 - - 
25 0.1 9.0 - - 
26 0.6 15 - - 
27 † † † † 
28 2.2 0.6 - - 
29 1.5 9.7 - - 
30 0.4 4.5 - - 
31 0.3 32 - - 
32 0.7 6.3 - - 
33 1.2 7.3 - - 
* Detected below the lower limit of quantitation 
** Detected outside the allowed 20% ratio range 
*** Detected below the lower limit of quantitation and outside of 20% ratio range 
† Sample 27 Omitted due to suspected contamination 






Table 14. (continued) 
Sample # Tramadol Trazodone 
1 - - 
2 1.0 - 
3 2.9 0.1 
4 - - 
5 - 0.2 
6 3.5 - 
7 1.5 - 
8 0.2 - 
9 - - 
10 2.5 0.2 
11 2.1 0.1 
12 0.1 0.3 
13 14 - 
14 4.1 - 
15 2.2 0.1 
16 0.4 - 
17 0.2 - 
18 0.6 - 
19 0.3 - 
20 0.7 0.1 
21 0.5 - 
22 - 0.1 
23 0.3 0.1 
24 1.9 0.1 
25 6.0 - 
26 - - 
27 † † 
28 0.1 - 
29 2.6 - 
30 7.4 - 
31 0.1 - 
32 0.2 - 
33 1.0 0.1 
* Detected below the lower limit of quantitation 
** Detected outside the allowed 20% ratio range 
*** Detected below the lower limit of quantitation and outside of 20% ratio range 
† Sample 27 Omitted due to suspected contamination 






4.1.2 Second Waters UPLC-MS/MS Extraction Results 
 The results of the second batch of samples extracted and analyzed on the Waters are 
given in Table 15. Note that the 4 background samples were not re-extracted and analyzed a 
second time due to insufficient volume. 
Table 15. Concentrations of compounds observed in the second extraction of the 33 wastewater samples collected 
during the UF home football game. Compounds that were not observed as being present in any of the samples were 
removed from the table for clarity. Concentrations are reported in ng/mL.  
Sample # 7-Aminoclonazepam Amphetamine Benzoylecgonine Cocaine 
1 0.1 0.4 1.2 0.2 
2 - 0.4 1.8 0.4 
3 - 0.5 2.0 1.3 
4 - 0.5 0.6 0.6 
5 - 1.2 6.2 0.8 
6 - 1.0 1.0 0.6 
7 - 0.7 2.2 1.8 
8 - 1.0 2.0 0.3 
9 - 4.8 1.6 2.0 
10 - 0.2 3.3 5.0 
11 - 1.4 2.6 1.4 
12 - 1.1 1.2 1.6 
13 - 0.7 1.1 1.5 
14 - 2.8 2.6 0.9 
15 - 1.7 2.9 2.9 
16 - 2.7 14 0.8 
17 - 0.8 1.7 1.1 
18 - 1.0 1.7 0.9 
19 - 0.9 4.0 1.3 
20 - 2.6 4.9 0.7 
21 - 1.2 2.3 1.9 
22 - 2.2 0.6 0.8 
23 - 3.5 0.4 0.4 
24 - 0.3 0.8 2.7 
25 - 0.3 2.6 11 
26 - 1.0 0.1 * 
27 - 2.3 5.2 4.9 
28 - 2.4 0.1 0.2 
29 - 0.2 0.6 0.2 
30 - 0.5 10 3.5 
31 - 2.7 0.1 - 
32 - 2.6 0.3 * 
33 - 0.5 0.4 1.0 
* Detected below the lower limit of quantitation 
** Detected outside the allowed 20% ratio range 
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*** Detected below the lower limit of quantitation and outside of 20% ratio range 
 
Table 15. (continued) 
Sample # Codeine Cyclobenzaprine EDDP Hydrocodone 
1 - - - 0.3 
2 - - - 0.2 
3 - * - 0.1 
4 - - - 0.1 
5 0.1 - - - 
6 - - - 0.2 
7 - - - - 
8 - - 1.5 0.2 
9 0.4 - - 0.2 
10 - - - - 
11 - - - 0.1 
12 - - - 0.1 
13 - - * - 
14 0.1 - - 0.2 
15 - - - - 
16 - - - - 
17 - - - 0.1 
18 - - - - 
19 0.1 - - - 
20 0.1 - - 0.7 
21 - - - 0.7 
22 - - - 0.3 
23 - - - 0.3 
24 - - - 0.2 
25 0.2 - - *** 
26 - - * 0.2 
27 - - - - 
28 - - - - 
29 0.2 - - 0.1 
30 - - - 0.2 
31 - - - 0.1 
32 - - - 0.3 
33 - - - - 
* Detected below the lower limit of quantitation 
** Detected outside the allowed 20% ratio range 
*** Detected below the lower limit of quantitation and outside of 20% ratio range 
 
Table 15. (continued) 
Sample # Hydromorphone Ketamine MDMA Methadone 
1 - - - - 
2 - - - - 
3 - - - - 
4 - - - - 
5 - - - - 
6 - - - - 
7 - - - - 
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8 * 0.4 - 2.5 
9 - - - - 
10 - - - - 
11 - - - - 
12 - - - - 
13 - - - - 
14 - - 0.1 - 
15 - - - - 
16 - - - - 
17 - - - - 
18 - - - - 
19 - - - - 
20 * - - - 
21 - - - - 
22 - - - - 
23 - 0.3 1.3 - 
24 - - - - 
25 - - - - 
26 - - 0.1 - 
27 - - - - 
28 - - - - 
29 - - - - 
30 - - - - 
31 - - - - 
32 - - - - 
33 - - - - 
* Detected below the lower limit of quantitation 
** Detected outside the allowed 20% ratio range 




Table 15. (continued) 
Sample # Methamphetamine Methylphenidate Morphine Norhydrocodone 
1 - - - 0.4 
2 - - - 0.1 
3 - - 0.4 0.1 
4 - - - - 
5 0.2 - - - 
6 1.2 0.1 - 0.1 
7 - - - - 
8 - - 0.1 0.1 
9 - - - - 
10 - 0.1 - - 
11 0.6 - - 0.1 
12 - - - - 
13 - - - - 
14 0.2 - 0.1 0.2 
15 - - - - 
16 - - - - 
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17 - - - 0.1 
18 - - - - 
19 - - - - 
20 - - 1.3 0.4 
21 - - - 0.2 
22 - - - 0.1 
23 - - 0.2 0.2 
24 - - - 0.1 
25 - - - - 
26 - - - 0.1 
27 - - - - 
28 - - - - 
29 - - - 0.1 
30 - - - 0.1 
31 - - - 0.1 
32 - - - 0.1 
33 - - - - 
* Detected below the lower limit of quantitation 
** Detected outside the allowed 20% ratio range 





Table 15. (continued) 
Sample # Noroxycodone O-Desmethyltramadol Oxycodone Oxymorphone 
1 0.2 - 0.1 - 
2 0.3 - 0.3 0.1 
3 0.2 0.6 0.2 0.1 
4 - - - - 
5 0.1** - 0.1 0.1 
6 0.1 0.7 0.1 - 
7 - 0.3 * - 
8 - - - - 
9 - - * - 
10 - - - - 
11 - - - - 
12 0.1 - 0.1 - 
13 2.5 2.7 0.2 - 
14 0.4 2.8 0.3 0.1 
15 0.3 *** 0.3 - 
16 - - - - 
17 1.0 - 0.4 0.1 
18 0.2 - 0.5 - 
19 - - - - 
20 0.7 - 0.4 0.3 
21 0.3 - 0.2 - 
22 - - - - 
23 0.2 - 0.2 - 
24 0.1** 0.6 0.1 - 
25 - 0.9 - - 
26 *** - - - 
27 - - - - 
28 - - - - 
29 0.2 0.4 0.1 - 
30 0.3 1.1 0.2 - 
31 - - - - 
32 0.1 - * - 
33 0.6 - 0.3 - 
* Detected below the lower limit of quantitation 
** Detected outside the allowed 20% ratio range 





Table 15. (continued) 
Sample # Phentermine Pseudoephedrine Tapentadol Temazepam 
1 1.0 15 - - 
2 0.7 21 - - 
3 4.7 7.5 1.3 0.3 
4 0.3 1.6 - - 
5 2.3 2.1 - - 
6 0.5 5.4 - - 
7 1.4 6.1 - - 
8 0.1 2.9 - 0.1 
9 4.1 27 0.5 * 
10 0.9 6.7 - - 
11 0.1 13 - - 
12 0.1 6.2 - - 
13 - 5.7 - - 
14 1.5 10 - 0.1** 
15 1.5 7.2 - - 
16 3.7 7.2 - - 
17 - 8.0 - 0.4 
18 4.2 3.7 - - 
19 1.6 35 - - 
20 1.6 12 - 0.1 
21 0.1 16 - - 
22 2.3 1.8 - - 
23 3.2 13 - 0.2** 
24 1.5 62 - - 
25 0.1 7.6 - - 
26 0.3 8.1 - - 
27 0.1 6.5 - - 
28 3.0 0.8 - - 
29 1.7 10 - - 
30 0.5 5.3 - - 
31 0.3 31 - - 
32 1.0 8.6 - - 
33 1.9 12 - - 
* Detected below the lower limit of quantitation 
** Detected outside the allowed 20% ratio range 





Table 15. (continued) 
Sample # Tramadol Trazodone 
1 - - 
2 1.1** - 
3 2.8** * 
4 - - 
5 - * 
6 4.6 - 
7 1.9 - 
8 0.3** - 
9 - - 
10 2.4 * 
11 3.4 * 
12 0.1** 0.5 
13 15 - 
14 5.4 - 
15 1.0 * 
16 0.3** - 
17 0.3 - 
18 0.7 - 
19 0.3** - 
20 0.6 * 
21 0.4** - 
22 - * 
23 0.3** * 
24 2.2 * 
25 5.7 - 
26 - - 
27 0.4 - 
28 0.2** - 
29 2.9 - 
30 9.2 - 
31 0.2** - 
32 0.4 - 
33 1.4 * 
* Detected below the lower limit of quantitation 
** Detected outside the allowed 20% ratio range 





4.1.3 Shimadzu 8040 UFLC-MS/MS Data 
 The results of the second analysis of the wastewater samples performed on the Shimadzu, 
are given in Table 16.  
 
Table 16. Concentrations of compounds obtained from the extracted wastewater samples on the Shimadzu UFLC-
MS/MS. Compounds that were not observed as being present in any of the samples were removed from the table for 
clarity. Concentrations are reported in ng/mL.  
Sample # 7-Aminoclonazepam Amphetamine Benzoylecgonine Cocaine 
1 0.1** 0.3 1.3 N/A 
2 - 0.3 1.8 N/A 
3 - 0.4 1.8 N/A 
4 - 0.4 0.5 N/A 
5 - 1.0 6.1 N/A 
6 - 0.9 0.9 N/A 
7 - 0.6 2.1 N/A 
8 - 0.8 1.9 N/A 
9 - 6.5 1.4 N/A 
10 - 0.2 3.5 N/A 
11 - 1.3 2.6 N/A 
12 - 1.0 1.2 N/A 
13 - 0.5 1.1 N/A 
14 - 3.1 2.6 N/A 
15 - 1.5 2.8 N/A 
16 - 2.3 14 N/A 
17 - 0.6 1.7 N/A 
18 - 0.9 1.5 N/A 
19 - 0.8 4.0 N/A 
20 - 2.2 4.6 N/A 
21 - 1.1 2.2 N/A 
22 - 1.7 0.5 N/A 
23 - 3.1 0.4 N/A 
24 - 0.3 0.8 N/A 
25 - 0.3 2.4 N/A 
26 - 0.8 0.1 N/A 
27 - 2.4 4.8 N/A 
28 - 2.0 0.1 N/A 
29 - 0.2 0.5 N/A 
30 - 0.3 9.8 N/A 
31 - 2.3 0.1 N/A 
32 - 1.9 0.3 N/A 
33 - 0.5 0.3 N/A 
 
* Detected below the lower limit of quantitation 
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** Detected outside the allowed 20% ratio range 
*** Detected below the lower limit of quantitation and outside of 20% ratio range 
**** Detected above the upper limit of quantitation 





Table 16. (continued) 
Sample # Codeine Cyclobenzaprine EDDP Hydrocodone 
1 - N/A - 0.4 
2 - N/A - 0.3 
3 - N/A - 0.1 
4 - N/A - 0.1 
5 *** N/A - - 
6 - N/A - 0.3 
7 - N/A - - 
8 - N/A 1.3 0.2 
9 0.4 N/A - 0.2 
10 - N/A - - 
11 - N/A - 0.2 
12 - N/A - 0.1 
13 - N/A * - 
14 0.1 N/A - 0.1 
15 - N/A - - 
16 - N/A - - 
17 - N/A - 0.1 
18 - N/A - - 
19 0.1 N/A - - 
20 0.1 N/A - 0.8 
21 - N/A - 1.0 
22 - N/A - 0.4 
23 - N/A - 0.5 
24 - N/A - 0.2 
25 0.2 N/A - 0.1 
26 - N/A * 0.3 
27 - N/A - - 
28 - N/A - - 
29 0.2 N/A - 0.2 
30 - N/A - 0.4 
31 - N/A - 0.2 
32 - N/A - 0.4 
33 - N/A - - 
 
* Detected below the lower limit of quantitation 
** Detected outside the allowed 20% ratio range 
*** Detected below the lower limit of quantitation and outside of 20% ratio range 
**** Detected above the upper limit of quantitation 





Table 16. (continued) 
Sample # Hydromorphone Ketamine MDMA Methadone 
1 - - - - 
2 - - - - 
3 - - - - 
4 - - - - 
5 - - - - 
6 - - - - 
7 - - - - 
8 0.1 0.4 - * 
9 - - - - 
10 - - - - 
11 - - - - 
12 - - - - 
13 - - - - 
14 - - 0.1 - 
15 - - - - 
16 - - - - 
17 - - - - 
18 - - - - 
19 - - - - 
20 0.1 - - - 
21 - - - - 
22 - - - - 
23 - 0.2 2.3 - 
24 - - - - 
25 - - - - 
26 - - 0.1 - 
27 - - - - 
28 - - - - 
29 - - - - 
30 - - - - 
31 - - - - 
32 - - - - 
33 - - - - 
 
* Detected below the lower limit of quantitation 
** Detected outside the allowed 20% ratio range 
*** Detected below the lower limit of quantitation and outside of 20% ratio range 
**** Detected above the upper limit of quantitation 





Table 16. (continued) 
Sample # Methamphetamine Methylphenidate Morphine Norhydrocodone 
1 - N/A - 0.2 
2 - N/A - 0.1 
3 - N/A 0.5 * 
4 - N/A - - 
5 0.2 N/A - - 
6 1.7 N/A - 0.1 
7 - N/A - - 
8 - N/A 0.1 * 
9 - N/A - - 
10 - N/A - - 
11 0.8 N/A - *** 
12 - N/A - - 
13 - N/A - - 
14 0.2 N/A 0.1 0.1 
15 - N/A - - 
16 - N/A - - 
17 - N/A - *** 
18 - N/A - - 
19 - N/A - - 
20 - N/A 1.2 0.1 
21 - N/A - 0.1 
22 - N/A - * 
23 - N/A 0.2 0.1 
24 - N/A - * 
25 - N/A - - 
26 - N/A - * 
27 - N/A - - 
28 - N/A - - 
29 - N/A - * 
30 - N/A - * 
31 - N/A - * 
32 - N/A - * 
33 - N/A - - 
 
* Detected below the lower limit of quantitation 
** Detected outside the allowed 20% ratio range 
*** Detected below the lower limit of quantitation and outside of 20% ratio range 
**** Detected above the upper limit of quantitation 





Table 16. (continued) 
Sample # Noroxycodone O-Desmethyltramadol Oxycodone Oxymorphone 
1 0.1 N/A 0.2 - 
2 0.2 N/A 0.3 0.1 
3 0.1 N/A 0.2 0.1 
4 - N/A - - 
5 0.1 N/A 0.1 0.1 
6 0.1 N/A 0.1 - 
7 - N/A 0.1 - 
8 - N/A - - 
9 - N/A 0.1 - 
10 - N/A - - 
11 - N/A - - 
12 0.1 N/A 0.1 - 
13 1.1 N/A 0.2 - 
14 0.2 N/A 0.4 0.2 
15 0.2 N/A 0.3 - 
16 - N/A - - 
17 0.4 N/A 0.5 0.1 
18 * N/A 0.6 - 
19 - N/A - - 
20 0.5 N/A 0.4 0.5 
21 0.1 N/A 0.2 - 
22 - N/A - - 
23 0.1 N/A 0.2 - 
24 * N/A 0.1 - 
25 - N/A - - 
26 * N/A - - 
27 - N/A - - 
28 - N/A - - 
29 * N/A 0.2 - 
30 0.1 N/A 0.3 - 
31 - N/A - - 
32 * N/A 0.1 - 
33 0.3 N/A 0.4 - 
 
* Detected below the lower limit of quantitation 
** Detected outside the allowed 20% ratio range 
*** Detected below the lower limit of quantitation and outside of 20% ratio range 
**** Detected above the upper limit of quantitation 




Table 16. (continued) 
Sample # Phentermine Pseudoephedrine Tapentadol Temazepam 
1 N/A N/A - - 
2 N/A N/A - - 
3 N/A N/A 1.6 0.6 
4 N/A N/A - - 
5 N/A N/A - - 
6 N/A N/A - - 
7 N/A N/A - - 
8 N/A N/A - 0.1 
9 N/A N/A 0.8 0.1 
10 N/A N/A - - 
11 N/A N/A - - 
12 N/A N/A - - 
13 N/A N/A - - 
14 N/A N/A - 0.1 
15 N/A N/A - - 
16 N/A N/A - - 
17 N/A N/A - 0.6 
18 N/A N/A - - 
19 N/A N/A - - 
20 N/A N/A - 0.2 
21 N/A N/A - - 
22 N/A N/A - - 
23 N/A N/A - 0.3 
24 N/A N/A - - 
25 N/A N/A - - 
26 N/A N/A - - 
27 N/A N/A - - 
28 N/A N/A - - 
29 N/A N/A - - 
30 N/A N/A - - 
31 N/A N/A - - 
32 N/A N/A - - 
33 N/A N/A - - 
 
* Detected below the lower limit of quantitation 
** Detected outside the allowed 20% ratio range 
*** Detected below the lower limit of quantitation and outside of 20% ratio range 
**** Detected above the upper limit of quantitation 




Table 16. (continued) 
Sample # Tramadol Trazodone 
1 - N/A 
2 1.2 N/A 
3 3.1 N/A 
4 - N/A 
5 - N/A 
6 5.5 N/A 
7 2.1 N/A 
8 * N/A 
9 - N/A 
10 2.2 N/A 
11 3.7 N/A 
12 *** N/A 
13 19**** N/A 
14 6.2 N/A 
15 1.2 N/A 
16 0.5 N/A 
17 * N/A 
18 0.9 N/A 
19 0.5 N/A 
20 0.8 N/A 
21 0.6 N/A 
22 - N/A 
23 * N/A 
24 2.7 N/A 
25 5.2 N/A 
26 - N/A 
27 0.6 N/A 
28 * N/A 
29 3.4 N/A 
30 11**** N/A 
31 * N/A 
32 0.5 N/A 
33 1.5 N/A 
 
* Detected below the lower limit of quantitation 
** Detected outside the allowed 20% ratio range 
*** Detected below the lower limit of quantitation and outside of 20% ratio range 
**** Detected above the upper limit of quantitation 





 Final concentrations for each sample were reported based on the results obtained from all 
three (3) analyses. Compounds of interest present in the Shimadzu UFLC-MS/MS method were 
reported in Table 17 as observed. The reasoning behind this decision is the Shimadzu is method is 
validated for urine and has a history of regular, reliable performance screening clinical samples. 
Therefore, while the Shimadzu method is not validated for wastewater samples, the possibility of 
instrumental error on the Waters can be ruled out for the Shimadzu. 
For drugs not present in the Shimadzu method, an average of the two concentrations 
obtained from the Waters UPLC-MS/MS analyses is also reported in Table 17. All final 
concentrations are considered semi-quantitative since neither the Waters nor Shimadzu analysis 
methods are validated for wastewater. Concentrations were rounded up to 2 significant figures. 
Figure 5 contains a breakdown of the number of samples containing at least one drug from each 
class.  
Table 17. Final concentrations for each of the game day samples based on the three analysis. Analytes present in the 
Shimadzu method were reported as detected. Concentrations of analytes present only on the Waters were reported as an 
average of the two analyses. Compounds that were not observed as being present in any of the samples were removed 
from the table for clarity. Concentrations are reported in ng/mL.  
Sample # 7-Aminoclonazepam Amphetamine Benzoylecgonine Cocaine 
1 0.1 0.3 1.3 0.3 
2 - 0.3 1.8 0.4 
3 - 0.4 1.8 1.6 
4 - 0.4 0.5 0.7 
5 - 1.0 6.1 1.3 
6 - 0.9 0.9 0.5 
7 - 0.5 2.1 1.5 
8 - 0.8 1.9 0.4 
9 - 6.5 1.4 1.6 
10 - 0.2 3.5 5.0 
11 - 1.3 2.6 1.3 
12 - 1.0 1.2 1.9 
13 - 0.5 1.1 1.3 
14 - 3.1 2.6 0.9 
15 - 1.4 2.8 4.0 
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Sample # 7-Aminoclonazepam Amphetamine Benzoylecgonine Cocaine 
16 - 2.3 14 0.8 
17 - 0.6 1.7 1.1 
18 - 0.9 1.5 0.9 
19 - 0.8 4.0 1.2 
20 - 2.2 4.6 0.8 
21 - 1.1 2.2 2.0 
22 - 1.7 0.5 0.7 
23 - 3.1 0.4 0.5 
24 - 0.3 0.8 2.5 
25 - 0.2 2.4 11 
26 - 0.8 0.1 0.1 
27 - 2.4 4.8 4.9 
28 - 2.0 0.1 0.1 
29 - 0.2 0.5 0.2 
30 - 0.3 9.8 3.1 
31 - 2.3 0.1 - 
32 - 1.9 0.3 0.1 





Table 17. (continued) 
Sample # Codeine Cyclobenzaprine EDDP Hydrocodone 
1 - - - 0.4 
2 - - - 0.3 
3 - 0.6 - 0.1 
4 - - - 0.1 
5 0.1 - - - 
6 - - - 0.3 
7 - - - - 
8 - - 1.3 0.2 
9 0.4 - - 0.2 
10 - - - - 
11 - - - 0.2 
12 - - - 0.1 
13 - - 0.1 - 
14 0.1 - - 0.1 
15 - - - - 
16 - - - - 
17 - - - 0.1 
18 - - - - 
19 0.1 - - - 
20 0.1 - - 0.8 
21 - - - 1.0 
22 - - - 0.4 
23 - - - 0.5 
24 - - - 0.2 
25 0.2 - - 0.1 
26 - - 0.1 0.3 
27 - - - - 
28 - - - - 
29 0.2 - - 0.2 
30 - - - 0.4 
31 - - - 0.2 
32 - - - 0.4 





Table 17. (continued) 
Sample # Hydromorphone Ketamine MDMA Methadone 
1 - - - - 
2 - - - - 
3 - - - - 
4 - - - - 
5 - - - - 
6 - - - - 
7 - - - - 
8 0.1 0.3 - 1.1 
9 - - - - 
10 - - - - 
11 - - - - 
12 - - - - 
13 - - - - 
14 - - 0.1 - 
15 - - - - 
16 - - - - 
17 - - - - 
18 - - - - 
19 - - - - 
20 0.1 - - - 
21 - - - - 
22 - - - - 
23 - 0.2 2.1 - 
24 - - - - 
25 - - - - 
26 - - 0.1 - 
27 - - - - 
28 - - - - 
29 - - - - 
30 - - - - 
31 - - - - 
32 - - - - 





Table 17. (continued) 
Sample # Methamphetamine Methylphenidate Morphine Norhydrocodone 
1 - - - 0.2 
2 - - - 0.1 
3 - - 0.5 - 
4 - - - - 
5 0.2 - - - 
6 1.7 0.1 - 0.6 
7 - - - - 
8 - - 0.1 0.7 
9 - - - - 
10 - 0.1 - - 
11 0.8 - - - 
12 - - - - 
13 - - - - 
14 0.2 - 0.1 0.1 
15 - - - - 
16 - - - - 
17 - - - - 
18 - - - - 
19 - - - - 
20 - - 1.2 0.1 
21 - - - 0.1 
22 - - - - 
23 - - 0.2 0.1 
24 - - - - 
25 - - - - 
26 - - - - 
27 - - - - 
28 - - - - 
29 - - - - 
30 - - - - 
31 - - - - 
32 - - - - 





Table 17. (continued) 
Sample # Noroxycodone O-Desmethyltramadol Oxycodone Oxymorphone 
1 0.1 - 0.2 - 
2 0.2 - 0.3 0.1 
3 0.1 0.7 0.2 0.1 
4 - - - - 
5 0.1 - 0.1 0.1 
6 0.1 0.7 0.1 - 
7 - 0.3 0.1 - 
8 - - - - 
9 - - 0.1 - 
10 - - - - 
11 - - - - 
12 0.1 - 0.1 - 
13 1.1 3.6 0.2 - 
14 0.2 2.2 0.4 0.2 
15 0.2 0.6 0.3 - 
16 - - - - 
17 0.4 - 0.5 0.1 
18 0.2 - 0.6 - 
19 - - - - 
20 0.5 - 0.4 0.5 
21 0.1 - 0.2 - 
22 - - - - 
23 0.1 - 0.2 - 
24 - 0.6 0.1 - 
25 - 1.1 - - 
26 - - - - 
27 - - - - 
28 - - - - 
29 0.1 0.5 0.2 - 
30 0.1 1.4 0.3 - 
31 - - - - 
32 0.1 - 0.1 - 





Table 17. (continued) 
Sample # Phentermine Pseudoephedrine Tapentadol Temazepam 
1 0.8 12 - - 
2 0.7 23 - - 
3 4.7 8.6 1.6 0.6 
4 0.3 2.0 - - 
5 2.3 2.3 - - 
6 0.4 4.9 - - 
7 1.3 6.0 - - 
8 0.1 3.0 - 0.1 
9 3.3 23 0.8 0.1 
10 0.9 7.4 - - 
11 0.1 11 - - 
12 0.1 10 - - 
13 - 6.4 - - 
14 1.3 10 - 0.1 
15 2.5 13 - - 
16 4.3 8.7 - - 
17 - 8.4 - 0.6 
18 4.4 4.1 - - 
19 1.5 35 - - 
20 1.7 13 - 0.2 
21 0.1 22 - - 
22 2.0 1.6 - - 
23 3.4 15 - 0.3 
24 1.4 68 - - 
25 0.1 8.4 - - 
26 0.5 12 - - 
27 0.1 6.5 - - 
28 2.6 0.7 - - 
29 1.6 9.9 - - 
30 0.5  4.9 - - 
31 0.3 32 - - 
32 0.9 7.4 - - 





Table 17. (continued) 
Sample # Tramadol Trazadone 
1 - - 
2 1.2 - 
3 3.1 0.1 
4 - - 
5 - 0.2 
6 5.5 - 
7 2.1 - 
8 - - 
9 - - 
10 2.2 0.2 
11 3.7 0.1 
12 - 0.3 
13 14 - 
14 6.2 - 
15 1.2 0.1 
16 0.5 - 
17 0.2 - 
18 0.9 - 
19 0.5 - 
20 0.8 0.1 
21 0.6 - 
22 - 0.1 
23 - 0.1 
24 2.7 0.1 
25 5.2 - 
26 - - 
27 0.6 - 
28 - - 
29 3.4 - 
30 8.3 - 
31 - - 
32 0.5 - 
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5.1 Interpreting Final Results 
 In order to properly interpret the drug concentrations obtained from this study, the 
relationship between parent drugs and their metabolites should be understood. The presence of 
both the parent drug and any screened for metabolites will prove important in correlating WBE 
data back to the sampled population. Some pharmacologically active metabolites are prescribed 
on their own and thus observed concentrations may not necessarily be correlated to the parent 
compound. Other metabolites can be the product of various different parent compounds. While 
the results of this study provide a proof of concept more than anything else, discussion as to 
which metabolites could be the result of parental drug use only and which may have been 
consumed in the metabolized form is important. 
5.1.1 Opioids 
The consumption of the opiate codeine can sometimes be difficult to differentiate from 
the use of its major metabolite morphine and minor metabolite hydrocodone24,30. Both 
hydrocodone and morphine are metabolized to some extent into hydromorphone27. Hydrocodone 
use can be differentiated from morphine use by the presence of its unique metabolite 
norhydrocodone27.  
Codeine was detected in samples 5, 9, 14, 19, 20, 25, and 29 at concentration below 0.5 
ng/mL. Samples 5 and 19 contained only the parent compound and no metabolites. 
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Samples 14 and 20 also contained codeine’s major metabolite morphine at a similar 
concentration, although the concentration of morphine in sample 20, 1.2 ng/mL, was much higher 
than codeine, 0.1 ng/mL. The metabolite of minor morphine and hydrocodone, hydromorphone, 
was also detected in sample 20. Both samples also contained codeine’s minor metabolite 
hydrocodone and its subsequent metabolite norhydrocodone at similar levels to both codeine and 
morphine, 0.1 ng/mL. This indicated the possibility of metabolite use in both samples, along with 
the consumption of codeine directly. Hydrocodone was also detected in samples 9, 25, and 29 at 
concentrations similar to codeine, indicating the possibility of its use within these samples as 
well.  
Morphine without the presence of codeine was detected in samples 3, 8, and 23. 
Hydromorphone was also detected in sample 8. This indicates that the morphine detected in these 
samples is more likely the result of direct use or as a metabolite of another opioid such as heroin. 
The metabolite of heroin 6-MAM was not detected in any samples and as such the presence of 
morphine cannot be related back to heroin. This could be the result of poor stability for 6-MAM 
within wastewater however. Hydrocodone was detected without the presence of codeine in 
samples 1, 2, 3, 4, 6, 8, 11, 12, 17, 21, 22, 23, 24, 26, 30, 31, and 32 along with norhydrocodone 
in samples 1, 2, 6, 8, 21, and 23. This indicates that hydrocodone is likely present in these 
samples due to its direct consumption than as a product of codeine use within the samples 
population.   
The other opioids screened for within this study are less difficult to differentiate. 
Oxycodone, a semisynthetic opioid, is metabolized into both noroxycodone and oxymorphone31. 
Buprenorphine, another semisynthetic opioid, has the major urinary metabolite norbuprenorphine. 
Methadone’s major metabolite is EDDP24. The first fully synthetic opioid meperidine’s 
metabolite is normeperidine24. The major metabolite of the synthetic opioid fentanyl present in 
urine is norfentanyl32. Norcarfentanil is the major metabolite of carfentanil, but is also the 
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metabolite of remifentanil, a fentalog used medicinally for general anesthesia33. Lastly, O-
desmethyltramadol is the major metabolite of tramadol. 
Oxycodone was detected in samples 1, 2, 3, 5, 6, 7, 9, 12, 13, 14, 15, 17, 18, 20, 21, 23, 
24, 29, 30, 32, and 33. Samples 7, 9, and 24 contained only the parent drug, samples 2, 3, 5, 14, 
17, and 20 contained both noroxycodone and oxymorphone, and samples 1, 6, 7, 12, 13, 15, 18, 
21, 23, 29, 30, 32, and 33 contained only noroxycodone. None of the samples contained only a 
metabolite of oxycodone without the parent compound. Methadone was only detected in sample 8 
while its metabolite EDDP was detected in samples 8, 13, and 26. Tramadol was detected in 
samples 2, 3, 6, 7, 10, 11, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 27, 29, 30, 32, and 33 while 
it’s metabolite O-desmethyltramadol was only detected in samples 3, 6, 7, 13, 14, 15, 24, 25, 29, 
and 30. None of the samples where O-desmethyltramadol was detected did not also contain 
tramadol. The parent compounds buprenorphine, meperidine, fentanyl, and carfentanil and their 
metabolites were not detected in any of the samples.  
5.1.2 Benzodiazepines  
 The majority of benzodiazepines screened for in this analysis do not share metabolites 
with the exception of diazepam. Diazepam is metabolized into nordiazepam and temazepam34. 
Temazepam is then further metabolized into oxazepam35. Only of these 4 analytes screened for in 
the analysis, only temazepam was present in any samples. Some other benzodiazepine 
metabolites included in this screen worth discussing are α-hydroxyalprazolam and 7-
aminoclonzepam. Alprazolam is metabolized into α-hydroxyalprazolam but neither were detected 
in any samples. 7-aminoclonzepam is the metabolite of the benzodiazepine clonazepam, which 
was not included in this studies analysis screen since it is often difficult to detect in urine36. Only 





 The only non-illicit CNS stimulant metabolite screened for in this study was 
amphetamine, which was detected at some level in every sample. Amphetamine is also the 
metabolite of the illicit substance methamphetamine which was not detected in every sample. As 
such, it’s difficult to draw a conclusion as to the cause of the prevalence of amphetamine 
observed. 
5.1.4 Illicits 
 None of the illicit metabolites screened for can result from numerous parent drugs with 
the exception of amphetamine which itself is a commonly consumed parent compound. 
Methamphetamine was present in samples 5, 6, 11, and 14 while amphetamine was present in 
every sample. Therefore, it can be assumed that at least some of the amphetamine observed in 
samples 5, 6, 11, and 14 was the result of methamphetamine metabolism. The metabolite of 
cocaine, benzoylecgonine, was present in every sample while the parent compound was also 
present in every sample except sample 31.  
5.1.5 Background Samples 
 The background samples were intended to provide a baseline concentration of any drugs 
or metabolites that might be residually present in the wastewater system prior to the UF football 
game. Table 18 provides a useful side-by-side comparison between 3 randomly selected game 
day samples from each sampling location and the background samples corresponding to those 
locations.  
Background 1, 2, and 4 all contained around 0.3 ng/mL of the cocaine metabolite 
benzoylecgonine, indicating the possibility of a similar baseline concentration. As mentioned in 
section 5.2.4, benzoylecgonine was present in every sample, however the majority of samples 
were greater than 0.3 ng/mL. In samples 26, 28, 31, 32, and 33 however, benzoylecgonine was 
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detected at a concentration below 0.3 ng/mL. The parent compound, cocaine, was also detected at 
a concentration of 0.1 ng/mL in background 2. Again, nearly every sample contained a detectable 
concentration of cocaine greater than 0.1 ng/mL with the exception of sample 32. Morphine was 
detected at a concentration of 0.1 ng/mL in both background 2 and 4. Similar concentrations of 
morphine were detected in samples 8 and 14. Tramadol was also detected in background 2 and 4 
at a concentration of 0.1 ng/mL and 0.2 ng/mL respectively. Sample 17 also contained a 
concentration of tramadol at 0.2 ng/mL. Pseudoephedrine was detected in background 2, 3, and 4 
at concentrations 0.4 ng/mL, 0.2 ng/mL, and 1.2 ng/mL respectively. Pseudoephedrine was 
detected in all 33 samples with many containing relatively high concentrations. In fact, only 
sample 28 contained a concentration of pseudoephedrine below 1.2 ng/mL at 0.7 ng/mL. Perhaps 
most concerning was the detection of trazodone in background 2 and 3 at a concentration of 0.1 
ng/mL. This is problematic as every sample containing trazodone was quantified at a low 
concentration, the highest being 0.3 ng/mL. Samples 3, 11, 15, 20, 22, 23, 24, and 33 all 
contained a concentration of trazodone near 0.1 ng/mL. Lastly, only background 4 contained a 
detectable concentration ketamine at 0.1 ng/mL and phentermine at 0.2 ng/mL. Samples 8, 11, 12, 
21, 25, and 27 contained a similar concentration of phentermine while the two samples containing 
ketamine, 8 and 23, were quantified at a slightly higher concentration of 0.3 and 0.2 ng/mL.  
In conclusion, the presence of these compound in the background samples indicates the 
possibility that their detection within the aforementioned samples was the result of a baseline 
concentration rather than active excretion by the sampled population. However, further 
background samples will need to be obtained in future studies to better identify these baseline 
concentrations. Overall, the background concentrations observed when the stadium was not in use 




Table 18. Comparison between selected game day samples 7, 8, and 9 and background samples corresponding to their 
sample collection location. 
Compound Name Sample 7 Background 1 Sample 8 Background 3 Sample 9 Background 4 
Benzoylecgonine 2.1 0.2 1.9 - 1.4 0.3 
Cocaine 1.5 - 0.4 - 1.6 - 
Ketamine - - 0.3 - - 0.1 
Morphine - - 0.1 - - 0.1 
Phentermine 1.3 - 0.1 - 3.3 0.2 
Pseudoephedrine 6.0 - 3.0 0.2 23 1.2 
Tramadol 2.1 - - - - 0.2 
Trazodone - - - 0.1 - 0.1 
 
5.2 Comparison with Other Sources 
 One of the major goals of WWBE is to verify drug abuse data already obtained through 
less reliable sources. One of the best sources of this information comes from SAMHSA, who 
issues annual nationwide drug use reports broken down from the national level to regional and 
state levels. Table 18 contains the illicit drug abuse data released in SAMHSA’s 2016-2017 
annual report for the state of Florida4. The most reportedly abused drug is cannabis, which was 
not analyzed for in this study. However, the next most reportedly misused drug was pain 
relievers. Many of the opioids detected in the 33 waste water samples analyzed, such as 
hydrocodone, oxycodone, and tramadol, are commonly prescribed for pain relief. While 
conclusions cannot be drawn about the nature of opioid consumption among the stadium 
attendees present during the UF home game, their presence in the waste water does not conflict 
with the SAMHSA report. Additionally, cocaine was the second most commonly reported illicit 
drug abused. Cocaine and its metabolite benzoylecgonine were detected in all 33 of the game day 
waste water samples. This again appears to agree with the SAMHSA report. Lastly, 
methamphetamine followed by heroin were listed after cocaine as drugs abused by the drug 
abusers polled by the surveys used in SAMHSA’s report. Methamphetamine was detected in 4 
samples, alongside its metabolite amphetamine which was detected in every sample. This would 
again imply that some methamphetamine use is occurring among the attendees excreting drugs 
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and metabolites into the stadium waste water system. No 6-MAM, the metabolite of heroin, was 
detected in the analyzed samples but the metabolite of 6-MAM, morphine was present. While the 
presence of morphine does not necessarily indict heroin use, its presence at least does not rule out 
the possibility of heroin use and thus does not conflict in any way with the SAMHSA report.  
Table 19. Select data obtained from the SAMHSA 2016-2017 annual drug use report for the state of Florida4.  
Measure 
Percentage of Users 12 
Years of Age or Older 
Past Year Cannabis Use 13.69 
Past Year Misuse of Pain Relievers 4.18 
Past Year Cocaine Use 1.96 
Past Year Methamphetamine Use 0.47 
Past Year Heroin Use 0.29 
 
5.3 Issues Encountered 
5.3.1 Validation of Waters HPLC-MS/MS Method 
 During the method development stage on the Waters HPLC-MS/MS, validation of 
calibration linearity was attempted on 2 separate occasions with no success. According to OSU-
FTTL validation guidelines, a minimum of 6 calibration curves containing at least 6 concentration 
levels evenly spaced over the entire quantification range are required for validation. On both 
occasions multiple analytes contained less than 6 calibration points within the 20% concentration 
accuracy range while those outside that range were excluded.  
 There are three possible reasons for these inconsistencies. The first possibility is 
instrumental error either within the HPLC or MS/MS. After developing a working 
chromatographic and quantitation method on the Waters, numerous instrumental errors occurred 
and were addressed. The first major problem presented itself in the form of RT shifts between 
each analysis run and was diagnosed as a LC pump failure. After replacing the pump hardware 
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this issue disappeared. Later during the first validation attempt some analytes would be missing 
from the 400c calibrator while be present in the other calibrators. This issue was partially 
addressed by updating the instruments software, replacing a faulty guard column, and adjusting 
the MS/MS tune file. However, similar issue would still occasionally occur during subsequent 
analyses. Misinjection by the autosampler was ruled out by reinjecting samples and by the fact 
that only select analytes were not being detected. Developing a method on a different instrument 
such as the Shimadzu 8040 would help eliminate this as a possible source of error.  
The next possibility is SPE error. There were several attempts to troubleshoot the SPE 
method with some success. Originally the SPE procedure developed for this study contained no 
pre-conditioning step because the SPE cartridges were said to be designed without a need for 
preconditioning. After speaking with SPEware technicians the preconditioning step described in 
Chapter III was introduced. After testing the updated solid phase extraction method, less 
variability was observed, but it was still present. The second variability in the SPE process was 
that of flow rate. While uniform pressure was applied to each cartridge during sample addition via 
the positive pressure manifold, variability in flow rate occurred, even among the calibrators 
which contained no particulate debris. It’s possible that the use of a different SPE cartridge could 
address this issue. 
Finally, a third possible cause of variability in calibrator concentrations post extraction 
could be human error. There are several opportunities within the extraction and analysis process 
to introduce human error but the most likely source is during solution preparation and SPE. While 
this is difficult to control for, an additional extraction on the same system showed that the results 
were consistent among multiple analysts. Therefore, while this did appear to reduce some of the 
observed variability, many analytes still required one or more calibrators and QCs to be excluded 




 As seen in Tables 8 and 9 of chapter III, the illicit compound THC and its major 
metabolite THCA were originally included in the LC-MS/MS method developed of this study. 
However, post extraction concentrations were observed to be very low with only the top three 
calibrators containing a detectable peak, often not within specified parameters. It’s likely that 
both THC and THCA are either lost at some point during the SPE procedure or retained by the 
cartridge sorbent during the elution phase. The acidification of the wastewater samples prior to 
addition and of the sorbent during preconditioning were done partially in an attempt to address 
this, with little success. Collecting WWBE data on THC and THCA, both compounds found 
within cannabis, is desirable because of the recent decriminalization of this schedule I substance 
at the State level. One proposed way to address the inability to extract these analytes using the 
current SPE method is to develop a separate SPE or liquid-liquid extraction (LLE) method to 
target both compounds.   
5.4 Future Work and Conclusions 
 Future work on this study will focus on developing a validated LC-MS/MS method, an 
extraction procedure for cannabinoids of interest, and ways to relate observed concentrations of 
the analytes of interest back to the sampled population. Additionally, glucuronide metabolites 
were not included in this studies analysis panel and no glucuronidase enzymes were added prior 
to SPE of the wastewater samples. A test was performed to see if the SPE procedure would cleave 
any glucuronide metabolite by extracting and analyzing a water sample containing 3 glucuronide 
metabolite standards. This glucuronide sample was extracted alongside an extracted positive 
control, prepared from the calibration stock solution, and negative water control. These three 
extracted samples were analyzed alongside an unextracted glucuronide water sample on the 
Shimadzu 8040. The results of this test revealed that the glucuronides had not been hydrolyzed 
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and were not detectable. Therefore, future studies should also explore the possibility of cleaving 
any glucuronides likely present in wastewater.  
 In conclusion, the hypothesis of this study, that drug and metabolite concentrations would 
be elevated during times when the football stadium is in use when compared to times when it 
isn’t, was confirmed. Overall this work showed that a LC-MS/MS analysis method can be 
developed for a large panel of drugs of abuse to screen wastewater for the purposes of WWBE. 
Furthermore, this study also demonstrated that wastewater samples obtained directly from the 
wastewater system during football games is a promising way to establish drug consumption 
trends within the attending population. The relative success of this study in identifying 26 of the 
56 compounds of interest at a semi-quantitative in at least one of each of the 33 wastewater 
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